Le pubblicazioni scientifiche
I risultati di tutti gli studi condotti dalla FIL vengono presentati ai maggiori congressi nazionali e internazionali e inviati per la pubblicazione a riviste recensite.
Di seguito l’elenco delle pubblicazioni direttamente derivanti da attività di ricerca FIL o lavori per cui la FIL ha fornito supporto scientifico ad altri promotori e partner di ricerca.
Cliccando sul titolo sarà possibile accedere direttamente a PubMed o ad altri portali in cui è possibile trovare gli abstract o, ove disponibili, i testi completi delle pubblicazioni.
| Anno | Rivista | Titolo | Autori | Istologia/tipo di studio | Nome studio |
|---|---|---|---|---|---|
| 2023 | Leukemia | Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II study | Annalisa Chiappella, Anna Dodero, Andrea Evangelista, Alessandro Re, Lorella Orsucci, Sara Usai, Claudia Castellino, Vittorio Stefoni, Antonio Pinto, Manuela Zanni, Rosanna Ciancia, Chiara Ghiggi, Francesca Rossi, Annalisa Arcari, Fiorella Ilariucci, Vittorio Ruggero Zilioli, Leonardo Flenghi, Melania Celli, Stefano Volpetti, Fabio Benedetti, Filippo Ballerini, Gerardo Musuraca, Riccardo Bruna, Caterina Patti, Francesco Leonardi, Luca Arcaini, Massimo Magagnoli, Federica Cavallo, Anisa Bermema, Alessandra Tucci, Carola Boccomini, Giovannino Ciccone, Cristiana Carniti, Stefano aldo Pileri, and Paolo Corradini | T-Cell Lymphoma, PTCL | PTCL13, romidepsin-CHOEP |
| 2023 | British journal of haematology | Biological features and outcome of diffuse large B-cell lymphoma associated with hepatitis C virus in elderly patients: Results of the prospective 'Elderly Project' by the Fondazione Italiana Linfomi | Annalisa Arcari 1, Valentina Tabanelli 2, Francesco Merli 3, Luigi Marcheselli 4, Michele Merli 5, Monica Balzarotti 6, Vittorio Ruggero Zilioli 7, Alberto Fabbri 8, Federica Cavallo 9, Gloria Margiotta Casaluci 10, Alessandra Tucci 11, Benedetta Puccini 12, Elsa Pennese 13, Alice Di Rocco 14, Manuela Zanni 15, Leonardo Flenghi 16, Guido Gini 17, Roberto Sartori 18, Annalisa Chiappella 19, Sara Veronica Usai 20, Monica Tani 21, Dario Marino 22, Luca Arcaini 23, Daniele Vallisa 1, Michele Spina 24 | HCV+, DLBCL | Elderly Project |
| 2023 | Int J Radiat Oncol Biol Phys | Peritransplant Radiation Therapy in Patients With Refractory or Relapsed Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant: Long-Term Results of a Retrospective Study of the Fondazione Italiana Linfomi | Mario Levis 1, Belinda A Campbell 2, Fabio Matrone 3, Lavinia Grapulin 4, Anna Di Russo 5, Michela Buglione 6, Ilenia Iamundo De Cumis 7, Gabriele Simontacchi 8, Patrizia Ciammella 9, Alessandro Magli 10, Giuliana Pascale 11, Sofia Meregalli 12, Michael MacManus 13, Giuseppe Fanetti 3, Francesca De Felice 4, Gabriella Furfaro 14, Giovannino Ciccone 15, Umberto Ricardi 14 | RT, Hodgkin Lymphoma, ASCT | |
| 2023 | Frontiers in Oncology | Comparison of first-line treatment with bendamustine plus rituximab versus R-CHOP for patients with follicular lymphoma grade 3A: Results of a retrospective study from the Fondazione Italiana Linfomi | Gloria Margiotta-Casaluci 1, Sara Bigliardi 2, Federica Cocito 3, Erika Meli 4, Luigi Petrucci 5, Maura Nicolosi 6, Ombretta Annibali 7, Carola Boccomini 6, Valentina Bozzoli 8, Alessia Castellino 9, Federica Cattina 10, Natalia Cenfra 11, Sabino Ciavarella 12, Sofya Kovalchuk 13, Francesco Rotondo 14, Angelo Fama 15, Jacopo Olivieri 16, Francesco Zaja 17 | FL grade 3 A | BR vs R-CHOP (FOLL12) |
| 2023 | Hemasphere | Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi | Manuel Gotti 1, Roberta Sciarra 1 2, Alessandro Pulsoni 3, Francesco Merli 4, Stefano Luminari 4 5, Caterina Zerbi 2, Livio Trentin 6, Alessandro Re 7, Chiara Rusconi 8, Simonetta Viviani 8, Andrea Rossi 9, Federica Cocito 10, Barbara Botto 11, Erika Meli 12, Antonello Pinto 13, Irene Dogliotti 14, Guido Gini 15, Benedetta Puccini 16, Francesca Ricci 17, Luca Nassi 18, Alberto Fabbri 19, Anna Marina Liberati 20, Michele Merli 21, Andrea Riccardo Filippi 22 23, Maurizio Bonfichi 1, Valentina Zoboli 1, Germana Tartaglia 3, Giorgia Annechini 3, Gianna Maria D'Elia 3, Ilaria Del Giudice 3, Isabel Alvarez 4, Andrea Visentin 6, Stefano Pravato 6, Daniela Dalceggio 7, Chiara Pagani 7, Silvia Ferrari 9, Caterina Cristinelli 2, Tanja Lazic 2, Virginia Valeria Ferretti 24, Umberto Ricardi 25, Luca Arcaini 1 2 | Nodular Lymphocyte-predominant Hodgkin Lymphoma, NLPHL | |
| 2023 | Blood Advances | Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the FIL MCL0208 trial | Simone Ferrero 1, Daniele Grimaldi 2, Elena Arrigoni 3, Mariapia Pironti 4, Gian Maria Zaccaria 5, Beatrice Alessandria 4, Elisa Genuardi 4, Gabriele De Luca 4, Marco Ghislieri 6, Rita Tavarozzi 7, Alice Di Rocco 8, Alessandro Re 9, Vittorio Stefoni 10, Federica Cavallo 11, Carola Boccomini 12, Monica Balzarotti 13, Vittorio Ruggero Zilioli 14, Filipa Moita 15, Luca Arcaini 16, Elisa Lucchini 17, Filippo Ballerini 18, Andrés J M Ferreri 19, Benedetta Puccini 20, Giuseppe A Palumbo 21, Sara Galimberti 22, Sergio Cortelazzo 23, Antonello Di Paolo 24, Marco Ladetto 25 | MCL, biomarkers | MCL0208 |
| 2023 | Blood Advances | Long term follow-up of Rituximab plus Bendamustine and Cytarabine (R-BAC) in elderly patients with newly diagnosed MCL | Maria Chiara Tisi 1, Riccardo Moia 2, Caterina Patti 3, Andrea Evangelista 4, Simone Ferrero 5, Michele Spina 6, Monica Tani 7, Barbara Botto 8, Melania Celli 9, Benedetta Puccini 10, Emanuele Cencini 11, Alice Di Rocco 12, Claudio Chini 13, Chiara Ghiggi 14, Renato Zambello 15, Manuela Zanni 16, Roberta Sciarra 17, Riccardo Bruna 2, Martina Ferrante 5, Stefano Aldo Pileri 18, Francesca Maria Quaglia 19, Caterina Stelitano 20, Alessandro Re 21, Stefano Volpetti 22, Vittorio Ruggero Zilioli 23, Annalisa Arcari 24, Francesco Merli 25, Carlo Visco 26 | MCL | R-BAC |
| 2023 | Blood Advances | A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphoma | Annalisa Arcari 1, Luigi Rigacci 2, Alessandra Tucci 3, Benedetta Puccini 4, Sara Veronica Usai 5, Federica Cavallo 6, Alberto Fabbri 7, Monica Balzarotti 8, Sabrina Pelliccia 9, Stefano Luminari 10, Elsa Pennese 11, Vittorio Ruggero Zilioli 12, Abdurraouf Mokhtar Mahmoud 13, Gerardo Musuraca 14, Dario Marino 15, Roberto Sartori 16, Barbara Botto 17, Guido Gini 18, Manuela Zanni 19, Stefan Hohaus 20, Giuseppe Tarantini 21, Leonardo Flenghi 22, Monica Tani 23, Alice Di Rocco 24, Michele Merli 25, Daniele Vallisa 26, Chiara Pagani 27, Luca Nassi 28, Daniela Dessì 29, Simone Ferrero 30, Emanuele Cencini 31, Patrizia Bernuzzi 32, Caterina Mammi 33, Luigi Marcheselli 34, Valentina Tabanelli 35, Michele Spina 36, Francesco Merli 37 | DLBCL | R-COMP vs R-CHOP |
| 2023 | Int J Radiat Oncol Biol Phys | A Quality Control Study on Involved Node Radiation Therapy in the European Organisation for Research and Treatment of Cancer/Lymphoma Study Association/Fondazione Italiana Linfomi H10 Trial on Stages I and II Hodgkin Lymphoma: Lessons Learned | Berthe M P Aleman 1, Umberto Ricardi 2, Richard W M van der Maazen 3, Paul Meijnders 4, Max Beijert 5, Angela Boros 6, Françoise Izar 7, Cécile P M Janus 8, Mario Levis 2, Valentine Martin 9, Lena Specht 10, Coreen Corning 11, Enrico Clementel 11, John M Raemaekers 12, Marc P André 13, Massimo Federico 14, Catherine Fortpied 11, Theodore Girinsky 9 | RT, involved node | EORTC/LySA/FIL 20051 - H10 |
| 2023 | Hematological oncology | Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naïve advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi | Maria E Nizzoli 1 2, Martina Manni 3, Chiara Ghiggi 4, Alessandro Pulsoni 5, Gerardo Musuraca 6, Michele Merli 7, Catello Califano 8, Alessia Bari 9, Massimo Massaia 10 11, Annarita Conconi 12, Pellegrino Musto 13, Donato Mannina 14, Tommasina Perrone 15, Francesca Re 16, Sara Galimberti 17, Guido Gini 18, Monia Capponi 19, Umberto Vitolo 20, Sara V Usai 21, Piero M Stefani 22, Filippo Ballerini 23, Anna M Liberati 24, Elsa Pennese 25, Domenico Pastore 26, Tetiana Skrypets 27, Hillary Catellani 2, Luigi Marcheselli 28, Massimo Federico 3, Stefano Luminari 1 3 | FL | FOLL12 |
| 2023 | Blood | Lenalidomide plus rituximab for the initial treatment of elderly frail patients with DLBCL: the FIL_ReRi Phase 2 Study | Guido Gini,1 Monica Tani,2 Alessandra Tucci,3 Luigi Marcheselli4, Marina Cesaretti4, Monica Bellei,4 Anna Pascarella,5 Filippo Ballerini,6 Mauro Petrini,1 Francesco Merli,7 Attilio Olivieri,1 Francesco Lanza,2 Ombretta Annibali,8 Vittorio Ruggero Zilioli,9 Anna Marina Liberati,10 Maria Chiara Tisi,11 Annalisa Arcari,12 Dario Marino,13 Gerardo Musuraca,14 Vincenzo Pavone,15 Alberto Fabbri,16 Samantha Pozzi,17 Donato Mannina,18 Caterina Plenteda,19 Melania Celli,20 and Stefano Luminari.7,21 | Elderly, DLBCL, frail | ReRi |
| 2022 | British journal of haematology | Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial | Chiappella A, Diop F, Agostinelli C, Novo M, Nassi L, Evangelista A, Ciccone G, Di Rocco A, Martelli M, Melle F, Moia R, Motta G, Righi S, Santambrogio E, Tucci A, Balzarotti M, Ladetto M, Pileri SA, Gaidano G, Vitolo U; Fondazione Italiana Linfomi (FIL). doi: 10.1111/bjh.17971. Epub ahead of print. | DLBCL, TP53 | DLCL04 |
| 2022 | Cancers | A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial | Gian Maria Zaccaria 1 2, Simone Ferrero 1, Eva Hoster 3, Roberto Passera 4, Andrea Evangelista 5, Elisa Genuardi 1, Daniela Drandi 1, Marco Ghislieri 6 7, Daniela Barbero 1, Ilaria Del Giudice 8, Monica Tani 9, Riccardo Moia 10, Stefano Volpetti 11, Maria Giuseppina Cabras 12, Nicola Di Renzo 13, Francesco Merli 14, Daniele Vallisa 15, Michele Spina 16, Anna Pascarella 17, Giancarlo Latte 18, Caterina Patti 19, Alberto Fabbri 20, Attilio Guarini 2, Umberto Vitolo 21, Olivier Hermine 22, Hanneke C Kluin-Nelemans 23, Sergio Cortelazzo 24, Martin Dreyling 25, Marco Ladetto 10 26 | MCL, Machine Learning | MCL0208 |
| 2022 | Hematological oncology | Brentuximab vedotin in The Treatment of Relapsed/Refractory CD30+ Peripheral T-cell Lymphoma: a FIL Phase 2 Study | Vittorio Stefoni 1 2, Cinzia Pellegrini 1, Lisa Argnani 2, Paolo Corradini 3, Anna Dodero 3, Lorella Orsucci 4, Stefano Volpetti 5, Pier Luigi Zinzani 1 2 doi: 10.1002/hon.2963. Online ahead of print. | CD30+ PTCL, brentuximab | |
| 2022 | Cancers | Second Cancers in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma: A Systematic Review by the Fondazione Italiana Linfomi | Luca Nassi 1, Vitaliana De Sanctis 2, Giacomo Loseto 3, Chiara Gerardi 4, Eleonora Allocati 4, Sabino Ciavarella 3, Carla Minoia 3, Attilio Guarini 3, Alessia Bari 5 | Long-term survival, survivorship, lymphoma survivor, Hodgkin lymphoma, DLBCL | |
| 2022 | Cancers | Late Cardiological Sequelae and Long-Term Monitoring in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: A Systematic Review by the Fondazione Italiana Linfomi | Stefano Oliva 1, Agata Puzzovivo 1, Chiara Gerardi 2, Eleonora Allocati 2, Vitaliana De Sanctis 3, Carla Minoia 4, Tetiana Skrypets 4, Attilio Guarini 4, Guido Gini 5 | Long-term survival, survivorship, lymphoma survivor, Hodgkin lymphoma, DLBCL | |
| 2022 | Cancers | Late Endocrine and Metabolic Sequelae and Long-Term Monitoring of Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: A Systematic Review by the Fondazione Italiana Linfomi | Sergio Di Molfetta 1, Antonella Daniele 2, Chiara Gerardi 3, Eleonora Allocati 3, Carla Minoia 4, Giacomo Loseto 4, Francesco Giorgino 1, Attilio Guarini 4, Vitaliana De Sanctis 5 | Long-term survival, survivorship, lymphoma survivor, Hodgkin lymphoma, DLBCL | |
| 2022 | Haematologica | Autologous stem cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study | Alejandro Martín García-Sancho 1, Monica Bellei 2, Miriam López-Parra 3, Giuseppe Gritti 4, María Cortés 5, Silvana Novelli 6, Carlos Panizo 7, Luigi Petrucci 8, Antonio Gutiérrez 9, Ivan Dlouhy 10, Mariana Bastos-Oreiro 11, Juan M Sancho 12, María J Ramírez 13, José M Moraleda 14, Estrella Carrillo 15, Ana I Jiménez-Ubieto 16, Isidro Jarque 17, Lorella Orsucci 18, Estefanía García-Torres 19, Carlos Montalbán 20, Anna Dodero 21, Reyes Arranz 22, Natalia De Las Heras 23, María J Pascual 24, Javier López-Jiménez 25, Michelle Spina 26, Alessandro Re 27, Sonia González De Villambrosia 28, Sabela Bobillo 29, Massimo Federico 30, Dolores Caballero 3 DOI: 10.3324/haematol.2021.279426 | ASCT, PTCL | GELTAMO/FIL study |
| 2022 | Leukemia | Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial | Andrés J M Ferreri # 1, Kate Cwynarski # 2, Elisa Pulczynski 3, Christopher P Fox 4, Elisabeth Schorb 5, Claudia Celico 6, Monica Falautano 6, Alessandro Nonis 7, Paul La Rosée 8, Mascia Binder 9, Alberto Fabbri 10, Fiorella Ilariucci 11, Mauro Krampera 12, Alexander Roth 13, Claire Hemmaway 14, Peter W Johnson 15, Kim M Linton 16, Tobias Pukrop 17, Jettes Sønderskov Gørløv 18, Monica Balzarotti 19, Georg Hess 20, Ulrich Keller 21, Stephan Stilgenbauer 22, Jense Panse 23, Alessandra Tucci 24, Lorella Orsucci 25, Francesco Pisani 26, Manuela Zanni 27, Stefan W Krause 28, Hans J Schmoll 29, Bernd Hertenstein 30, Mathias Rummel 31, Jeffery Smith 32, Lorenz Thurner 33, Giuseppina Cabras 34, Elsa Pennese 35, Maurilio Ponzoni 7, Martina Deckert 36, Letterio S Politi 19 37, Jurgen Finke 5, Antonella Ferranti 38, Kelly Cozens 39, Elvira Burger 40, Nicoletta Ielmini 41, Franco Cavalli 41 42, Emanuele Zucca 41 42, Gerald Illerhaus 43, IELSG32 study investigators | Extranodal, Primary CNS, DLBCL | IELSG32, MATRIx |
| 2022 | Blood | Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma | Simone Ferrero 1, Daniele Grimaldi 2, Elisa Genuardi 3, Daniela Drandi 3, Gian Maria Zaccaria 2, Beatrice Alessandria 3, Marco Ghislieri 4, Martina Ferrante 3, Andrea Evangelista 5, Barbara Mantoan 6, Gabriele De Luca 3, Piero Maria Stefani 7, Fabio Benedetti 8, Ivana Rita Casaroli 9, Manuela Zanni 10, Claudia Castellino 11, Vincenzo Pavone 12, Mario Petrini 13, Francesca Re 14, Stefan Hohaus 15, Gerardo Musuraca 16, Nicola Cascavilla 17, Chiara Ghiggi 18, Anna Marina Marina Liberati 19, Sergio Cortelazzo 20, Marco Ladetto 21 DOI: 10.1182/blood.2021014270 | MCL, MRD | MCL0208 |
| 2022 | Hematological oncology | Obinutuzumab does not improve complete methabolic response but does not compromise mobilization or engraftment of autologous peripheral blood stem cells in diffuse large B cell lymphoma: Results from a fondazione italiana linfomi prospective phase II study (the GIOTTO study) | Luigi Rigacci 1 2, Roberta Battistini 1, Sofia Kovalchuk 2, Valerio Zoli 1, Benedetta Puccini 2, Andrea Evangelista 3, Luca Arcaini 4 5, Leonardo Flenghi 6, Carlo Visco 7, Michael Mian 8, Alice Di Rocco 9, Claudia Peracchio 10, Manuel Gotti 4, Maria Chiara Tisi 7, Francesca Palombi 11, Samantha Pozzi 12, Daniela Gioia 10, Piera Viero 13, Maurizio Martelli 9 DOI: 10.1002/hon.3028 | DLBCL | GIOTTO |
| 2022 | Journal of clinical oncology | Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi | Michele Merli 1, Sara Rattotti 2, Michele Spina 3, Francesca Re 4, Marina Motta 5, Francesco Piazza 6, Lorella Orsucci 7, Andrés J M Ferreri 8, Omar Perbellini 9, Anna Dodero 10, Daniele Vallisa 11, Alessandro Pulsoni 12, Armando Santoro 13, Paolo Sacchi 14, Valentina Zuccaro 14, Emanuela Chimienti 3, Filomena Russo 4, Carlo Visco 15, Anna Linda Zignego 16, Luigi Marcheselli 17, Francesco Passamonti 1 18, Stefano Luminari 19 20, Marco Paulli 21 22, Raffaele Bruno 14 23, Luca Arcaini 2 22 DOI: 10.1200/JCO.22.00668 | HCV+, indolent B-cell lymphoma | BArT |
| 2022 | Blood | Ibrutinib improves survival compared to chemotherapy in mantle cell lymphoma with central nervous system relapse | Chiara Rusconi 1, Chan Y Cheah 2, Toby Andrew Eyre 3, David L Tucker 4, Pavel Klener 5, Eva Gine 6, Lara Crucitti 7, Cristina Muzi 7, Sara Iadecola 8, Gabriele Infante 9, Sophie Bernard 10, Rebecca Auer 11, Chiara Pagani 12, Monika Dlugosz-Danecka 13, Heidi Mocikova 14, Tom van Meerten 15, Emanuele Cencini 16, Ana Marín-Niebla 17, Michael E Williams 18, Piera Angelillo 19, Paolo Nicoli 20, Annalisa Arcari 21, Lucia Morello 22, Donato Mannina 23, Orsola Vitagliano 24, Roberto Sartori 25, Annalisa Chiappella 26, Roberta Sciarra 27, Piero Maria Stefani 28, Martin Dreyling 29, John F Seymour 30, Carlo Visco 31 DOI: 10.1182/blood.2022015560 | MCL, CNS relapse, ibrutinib | |
| 2022 | Hematological oncology | Characteristics and clinical outcomes of patients with ALK-positive anaplastic large cell lymphoma: Report from the prospective international T-cell lymphoma project | Carlos Chiattone 1, Monica Civallero 2, Thais Fischer 1, Eliana Miranda 3, Martina Manni 2, Natalia P C Zing 1, Stefano A Pileri 4, Silvia Montoto 5, Steven M Horwitz 6, Maria Elena Cabrera 7, Carmino A De Souza 3, Arnon Nagler 8, Stefano Luminari 9, Andrés J M Ferreri 10, Kenneth R Carson 11, Alessandro Re 12, Luigi Rigacci 13, Luca Nassi 14, Yana Stepanishyna 15, Massimo Federico 2, Giorgio Inghirami 16 PMID: 36083035 DOI: 10.1002/hon.3074 | ALK positive ALCL, PTCL | T-Cell Project |
| 2022 | Hematological oncology | The elderly prognostic index predicts early mortality in older patients with diffuse large B-cell lymphoma. An ad hoc analysis of the elderly project by the Fondazione Italiana Linfomi | Emanuele Cencini 1, Alessandra Tucci 2, Benedetta Puccini 3, Federica Cavallo 4, Stefano Luminari 5 6, Sara Veronica Usai 7, Alberto Fabbri 1, Elsa Pennese 8, Dario Marino 9, Vittorio Ruggero Zilioli 10, Monica Balzarotti 11, Luigi Petrucci 12, Agostino Tafuri 13, Annalisa Arcari 14, Barbara Botto 15, Manuela Zanni 16, Stefan Hohaus 17, Roberto Sartori 18, Michele Merli 19, Guido Gini 20, Wael Al Essa 21, Gerardo Musurca 22, Monica Tani 23, Luca Nassi 3, Rosa Daffini 2, Caterina Mammi 24, Luigi Marcheselli 25, Monica Bocchia 1, Michele Spina 26, Francesco Merli 5 | Elderly, DLBCL, EPI | Elderly Project |
| 2022 | Haematologica | Diffuse large B-cell lymphoma in octogenarians aged 85 and older can benefit from treatment with curative intent: a report on 129 patients prospectively registered in the Elderly Project of the Fondazione Italiana Linfomi (FIL) | Alessandra Tucci 1, Francesco Merli 2, Alberto Fabbri 3, Luigi Marcheselli 4, Chiara Pagani 5, Benedetta Puccini 6, Dario Marino 7, Manuela Zanni 8, Elsa Pennese 9, Leonardo Flenghi 10, Annalisa Arcari 11, Barbara Botto 12, Melania Celli 13, Caterina Mammi 14, Alessandro Re 5, Giulia Campostrini 5, Agostino Tafuri 15, Vittorio R Zilioli 16, Emanuele Cencini 3, Roberto Sartori 17, Chiara Bottelli 5, Michele Merli 18, Luigi Petrucci 19, Guido Gini 20, Monica Balzarotti 21, Federica Cavallo 22, Gerardo Musuraca 23, Stefano Luminari 24, Giuseppe Rossi 5, Michele Spina 25 | Elderly, DLBCL | Elderly Project |
| 2021 | Ital J Dermatol Venereol | Second neoplasm in cutaneous T-cell lymphoma patients: a marker of worse prognosis? | Pileri A1, Guglielmo A2, Fuligni F3, Lastrucci I4, Patrizi A2, Pimpinelli N4; Lymphoma Italian Foundation (Fondazione Italiana Linfomi, FIL), Cutaneous Lymphoma Task Force (Commissione Linfomi Cutanei), | T-Cell Lymphoma, cutaneous | |
| 2021 | The Lancet Haematology | Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial | Marco Ladetto 1, Sergio Cortelazzo 2, Simone Ferrero 3, Andrea Evangelista 4, Michael Mian 5, Rita Tavarozzi 6, Manuela Zanni 6, Federica Cavallo 3, Alice Di Rocco 7, Vittorio Stefoni 8, Chiara Pagani 9, Alessandro Re 9, Annalisa Chiappella 10, Monica Balzarotti 11, Vittorio R Zilioli 12, Maria Gomes da Silva 13, Luca Arcaini 14, Anna L Molinari 15, Filippo Ballerini 16, Andrés J M Ferreri 17, Benedetta Puccini 18, Fabio Benedetti 19, Piero M Stefani 20, Franco Narni 21, Ivana Casaroli 22, Caterina Stelitano 23, Giovannino Ciccone 4, Umberto Vitolo 10, Maurizio Martelli 7 | MCL, ASCT | MCL0208 |
| 2021 | British journal of haematology | A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL) | Carola Boccomini 1, Marco Ladetto 2, Luigi Rigacci 3 4, Benedetta Puccini 4, Sara Rattotti 5, Stefano Volpetti 6, Simone Ferrero 7, Annalisa Chiarenza 8, Roberto Freilone 9, Mattia Novo 10, Paolo Corradini 11, Luca Nassi 12, Chiara Rusconi 11 13, Caterina Stelitano 14, Silvia Bolis 15, Anna Marina Liberati 16, Alessandra Tucci 17, Luca Baldini 18, Monica Balzarotti 19, Andrea Evangelista 20, Giovannino Ciccone 20, Umberto Vitolo 1 | Elderly, FL | R-BM |
| 2021 | Tumori (Journal) | Management of lymphoma survivor patients in Italy: an evaluation by Fondazione Italiana Linfomi | Carla Minoia 1, Alessia Bari 2, Luca Nassi 3, Rita Banzi 4, Chiara Gerardi 4, Valentina Lenti 5, Marco Calabrese 5, Michele Spina 6, Attilio Guarini 1 | Long-term survival, survivorship, lymphoma survivor, Hodgkin lymphoma, DLBCL | |
| 2021 | Lancet Hematology | MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial | Andrés J M Ferreri 1, Jeanette K Doorduijn 2, Alessandro Re 3, Maria Giuseppina Cabras 4, Jeffery Smith 5, Fiorella Ilariucci 6, Mario Luppi 7, Teresa Calimeri 8, Chiara Cattaneo 3, Jahanzaib Khwaja 9, Barbara Botto 10, Claudia Cellini 11, Luca Nassi 12, Kim Linton 13, Pam McKay 14, Jacopo Olivieri 15, Caterina Patti 16, Francesca Re 17, Alessandro Fanni 4, Vikram Singh 5, Jacoline E C Bromberg 18, Kelly Cozens 19, Elisabetta Gastaldi 20, Massimo Bernardi 8, Nicola Cascavilla 21, Andrew Davies 22, Christopher P Fox 23, Maurizio Frezzato 24, Wendy Osborne 25, Anna Marina Liberati 26, Urban Novak 27, Renato Zambello 28, Emanuele Zucca 29, Kate Cwynarski 9, International Extranodal Lymphoma Study Group (IELSG) | Extranodal, Primary CNS, DLBCL | IELSG, MATRIx-RICE, MARIETTA |
| 2021 | Blood | ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project | Andrei Shustov 1 2, Maria Elena Cabrera 3, Monica Civallero 4, Monica Bellei 5, Young Hyeh Ko 6, Martina Manni 4, Tetiana Skrypets 4, Steven M Horwitz 7, Carmino Antonio De Souza 8, John A Radford 9, Sabela Bobillo 10, Maria Virginia Prates 11, Andrés J M Ferreri 12, Carlos Chiattone 13, Michele Spina 14, Julie M Vose 15, Annalisa Chiappella 16, Daniele Laszlo 17, Dario Marino 18, Caterina Stelitano 19, Massimo Federico 4 | ALK negative ALCL, PTCL | T-Cell Project |
| 2021 | Leukemia | Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study | Carlo Visco 1, Alice Di Rocco 2, Andrea Evangelista 3, Francesca Maria Quaglia 4, Maria Chiara Tisi 5, Lucia Morello 6, Vittorio Ruggero Zilioli 7, Chiara Rusconi 7 8, Stefan Hohaus 9, Roberta Sciarra 10, Alessandro Re 11, Cristina Tecchio 4, Annalisa Chiappella 8 12, Ana Marin-Niebla 13, Rory McCulloch 14, Guido Gini 15, Tommasina Perrone 16, Luca Nassi 17, Elsa Pennese 18, Piero Maria Stefani 19, Maria Christina Cox 20, Valentina Bozzoli 21, Alberto Fabbri 22, Valentina Polli 23, Simone Ferrero 24, Maria Isabel Alvarez De Celis 25, Antonello Sica 26, Luca Petrucci 2, Luca Arcaini 10, Simon Rule 14, Mauro Krampera 4, Umberto Vitolo 27, Monica Balzarotti 6 | MCL | MANTLE-FIRST |
| 2021 | Journal of clinical oncology | Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi | Francesco Merli 1, Stefano Luminari 1 2, Alessandra Tucci 3, Annalisa Arcari 4, Luigi Rigacci 5, Eliza Hawkes 6, Carlos S Chiattone 7 8, Federica Cavallo 9, Giuseppina Cabras 10, Isabel Alvarez 1, Alberto Fabbri 11, Alessandro Re 3, Benedetta Puccini 5, Allison Barraclough 12, Marcia Torresan Delamain 13, Simone Ferrero 9, Sara Veronica Usai 10, Angela Ferrari 1, Emanuele Cencini 11, Elsa Pennese 14, Vittorio Ruggero Zilioli 15, Dario Marino 16, Monica Balzarotti 17, Maria Christina Cox 18, Manuela Zanni 19, Alice Di Rocco 20, Arben Lleshi 21, Barbara Botto 22, Stefan Hohaus 23, Michele Merli 24, Roberto Sartori 25, Guido Gini 26, Luca Nassi 27, Gerardo Musuraca 28, Monica Tani 29, Chiara Bottelli 3, Sofia Kovalchuk 5, Francesca Re 30, Leonardo Flenghi 31, Annalia Molinari 32, Giuseppe Tarantini 33, Emanuela Chimienti 21, Luigi Marcheselli 34, Caterina Mammi 35, Michele Spina 21 | Elderly, DLBCL, sGA | Elderly Project |
| 2021 | Journal of clinical oncology | ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma | Grzegorz S Nowakowski 1, Annalisa Chiappella 2, Randy D Gascoyne 3, David W Scott 3, Qingyuan Zhang 4, Wojciech Jurczak 5, Muhit Özcan 6, Xiaonan Hong 7, Jun Zhu 8, Jie Jin 9, David Belada 10, Juan Miguel Bergua 11, Francesco Piazza 12, Heidi Mócikova 13, Anna Lia Molinari 14, Dok Hyun Yoon 15, Federica Cavallo 16, Monica Tani 17, Kazuhito Yamamoto 18, Koji Izutsu 19, Koji Kato 20, Myron Czuczman 21, Sarah Hersey 22, Adrian Kilcoyne 21, Jacqueline Russo 21, Krista Hudak 21, Jingshan Zhang 21, Steve Wade 23, Thomas E Witzig 1, Umberto Vitolo 2 | ABC, DLBCL | ROBUST |
| 2021 | British journal of haematology | Application of the Euro Clonality next-generation sequencing-based marker screening approach to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma patients: first data from the Fondazione Italiana Linfomi MCL0208 trial | Elisa Genuardi 1, Greta Romano 2 3 4, Marco Beccuti 2, Beatrice Alessandria 1, Donato Mannina 5, Catello Califano 6, Delia Rota Scalabrini 7, Sergio Cortelazzo 8, Marco Ladetto 9, Simone Ferrero 1 10, Raffaele A Calogero 11, Francesca Cordero 2 | MCL, Euro Clonality NGS | MCL0208 |
| 2021 | Cancers | Late Neurological and Cognitive Sequelae and Long-Term Monitoring of Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: A Systematic Review by the Fondazione Italiana Linfomi | Silvia Franceschetti 1, Maria Antonietta Annunziata 2, Giulia Agostinelli 2, Chiara Gerardi 3, Eleonora Allocati 3, Carla Minoia 4, Attilio Guarini 4 | Long-term survival, survivorship, lymphoma survivor, Hodgkin lymphoma, DLBCL | |
| 2021 | Cancers | Male and Female Fertility: Prevention and Monitoring Hodgkin' Lymphoma and Diffuse Large B-Cell Lymphoma Adult Survivors, A Systematic Review by the Fondazione Italiana Linfomi | Simonetta Viviani 1, Valentina Caccavari 2, Chiara Gerardi 3, Safaa Ramadan 1 4, Eleonora Allocati 3, Carla Minoia 5, Attilio Guarini 5, Anna Di Russo 6 | Long-term survival, survivorship, lymphoma survivor, Hodgkin lymphoma, DLBCL | |
| 2021 | Cancers | Long-Term Follow-Up of Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: Aims and Methodological Approach for Fondazione Italiana Linfomi Systematic Reviews | Chiara Gerardi 1, Eleonora Allocati 1, Carla Minoia 2, Attilio Guarini 2, Rita Banzi 1 | Long-term survival, survivorship, lymphoma survivor, Hodgkin lymphoma, DLBCL | |
| 2021 | Cancers | The Impact of Healthy Lifestyles on Late Sequelae in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors. A Systematic Review by the Fondazione Italiana Linfomi | Carla Minoia 1, Chiara Gerardi 2, Eleonora Allocati 2, Antonella Daniele 3, Vitaliana De Sanctis 4, Alessia Bari 5, Attilio Guarini 1 | Long-term survival, survivorship, lymphoma survivor, Hodgkin lymphoma, DLBCL | |
| 2021 | British journal of haematology | COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies | Passamonti F, Romano A, Salvini M, Merli F, Porta MGD, Bruna R, Coviello E, Romano I, Cairoli R, Lemoli R, Farina F, Venditti A, Busca A, Ladetto M, Massaia M, Pinto A, Arcaini L, Tafuri A, Marchesi F, Fracchiolla N, Bocchia M, Armiento D, Candoni A, Krampera M, Luppi M, Cardinali V, Galimberti S, Cattaneo C, La Barbera EO, Mina R, Lanza F, Visani G, Musto P, Petrucci L, Zaja F, Grossi PA, Bertù L, Pagano L, Corradini P; ITA-HEMA-COV Investigators* | Hematological malignancies, lymphoma, COVID19 | ITA-HEMA-COV |
| 2021 | Annals of Hematology | Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi | Armando Santoro # 1 2, Rita Mazza # 3, Michele Spina 4, Catello Califano 5, Giorgina Specchia 6, Michele Carella 7 8 9, Ugo Consoli 10, Francesca Palombi 11, Maurizio Musso 12, Alessandro Pulsoni 13, Sofya Kovalchuk 14, Maurizio Bonfichi 15, Francesca Ricci 3, Alberto Fabbri 16, Anna Marina Liberati 17, Marcello Rodari 18, Laura Giordano 19, Emanuela Chimienti 4, Monica Balzarotti 3, Roberto Sorasio 20, Andrea Gallamini 20 21, Chiara Ghiggi 7, Patrizia Ciammella 22, Umberto Ricardi 23, Stephane Chauvie 24, Carmelo Carlo-Stella 25 3, Francesco Merli 26 | Dose-dense ABVD, Hodgkin Lymphoma | FIL-ROUGE |
| 2021 | Hematological oncology | Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma | Elisa Genuardi 1, Petra Klous 2, Barbara Mantoan 1, Daniela Drandi 1, Martina Ferrante 1, Federica Cavallo 1 3, Beatrice Alessandria 1, Irene Dogliotti 1 3, Daniele Grimaldi 1 3, Simone Ragaini 1 3, Michele Clerico 1 3, Mariella Lo Schirico 1, Elona Saraci 4, Mehmet Yilmaz 2, Gian Maria Zaccaria 1, Sergio Cortelazzo 5, Umberto Vitolo 6, Stefano Luminari 7 8, Massimo Federico 8, Mario Boccadoro 1 3, Max van Min 2, Erik Splinter 2, Marco Ladetto 9, Simone Ferrero 1 3 | MCL, FL, targeted locus amplification | |
| 2021 | Tumori (Journal) | Fertility preservation strategies for patients with lymphoma: a real-world practice survey among Fondazione Italiana Linfomi centers | Simonetta Viviani1 , Miriam Dellino2, Safaa Ramadan1,3, Claudia Peracchio4, Luigi Marcheselli4, Carla Minoia5 and Attilio Guarini5, on behalf of the FIL Lymphoma Survivorship Committee | Long-term survival, survivorship, lymphoma survivor, Hodgkin lymphoma, DLBCL | |
| 2021 | Hemasphere | Quality Assessment for PCR-based Minimal Residual Disease in Lymphoma: 10 Years of Cross-laboratory Standardization Process Within the Fondazione Italiana Linfomi MRD Network | Barbara Mantoan 1, Elisa Genuardi 1, Martina Ferrante 1, Irene Della Starza 2 3, Elena Ciabatti 4, Susanna Grassi 4, Lucia Anna De Novi 2, Marzia Cavalli 2, Claudia Mannu 5, Anna Gazzola 5, Riccardo Bomben 6, Massimo Degan 6, Beatrice Alessandria 1, Christiane Pott 7, Marie-Hélène Delfau-Larue 8, Ramon García-Sanz 9, Claudio Agostinelli 5, Valter Gattei 6, Sara Galimberti 4, Ilaria Del Giudice 2, Gianluca Gaidano 10, Marco Ladetto 10 11, Simone Ferrero 1 12, Daniela Drandi 1 | MRD, PCR | |
| 2021 | Blood Advances | Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial | Umberto Ricardi 1, Mario Levis 2, Andrea Evangelista 3, Daniela Maria Gioia 4, Gian Mauro Sacchetti 5, Manuel Gotti 6, Alessandro Re 7, Michela Buglione 8, Vincenzo Pavone 9, Antonio Nardella 10, Luca Nassi 11, Manuela Zanni 12, Paola Franzone 12, Giovanni Piero Frezza 13, Alessandro Pulsoni 14, Lavinia Grapulin 15, Armando Santoro 16, Luigi Rigacci 17, Gabriele Simontacchi 18, Monica Tani 19, Francesco Zaja 20, Elisabetta Abruzzese 21, Barbara Botto 22, Vittorio Ruggero Zilioli 23, Delia Rota-Scalabrini 24, Roberto Freilone 25, Giovannino Ciccone 26, Andrea Riccardo Filippi 27, Pier Luigi Zinzani 28 | RT, Hodgkin lymphoma | HD0801 |
| 2021 | Leukemia & Lymphoma | Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi | Annalisa Arcari 1, Lucia Morello 2, Daniele Vallisa 1, Luigi Marcheselli 3, Cristina Tecchio 4, Francesca Maria Quaglia 4, Maria Chiara Tisi 5, Vittorio Ruggero Zilioli 6, Alice Di Rocco 7, Tommasina Perrone 8, Guido Gini 9, Irene Dogliotti 10, Nicola Bianchetti 11, Valentina Bozzoli 12, Chiara De Philippis 2, Maria Isabel Alvarez De Celis 13, Annalisa Chiappella 14 15, Alberto Fabbri 16, Matteo Pelosini 17, Michele Merli 18, Anna Lia Molinari 19, Roberta Sciarra 20, Stefano Volpetti 21, Stefan Hohaus 22, Luca Nassi 23, Carlo Visco 4 | MCL, Allo-transplantation | MANTLE-FIRST |
| 2021 | Blood Advances | A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study | Carlo Visco 1, Luigi Marcheselli 2, Roberto Mina 3, Marianna Sassone 4, Anna Guidetti 5, Domenico Penna 6, Chiara Cattaneo 7, Valentina Bonuomo 1, Alessandro Busca 8, Andrés J M Ferreri 9, Riccardo Bruna 10, Luigi Petrucci 11, Roberto Cairoli 12, Marco Salvini 13, Lorenza Bertù 14, Marco Ladetto 15, Sofia Pilerci 16, Antonello Pinto 17, Safaa Ramadan 18, Francesco Marchesi 19, Michele Cavo 20, Luca Arcaini 21, Elisa Coviello 22, Alessandra Romano 23, Pellegrino Musto 24, Massimo Massaia 25, Nicola Stefano Fracchiolla 26, Monia Marchetti 27, Annamaria Scattolin 28, Maria Chiara Tisi 29, Antonio Cuneo 30, Matteo G Della Porta 31, Livio Trentin 32, Mauro Turrini 33, Filippo Gherlinzoni 34, Agostino Tafuri 35, Sara Galimberti 36, Monica Bocchia 37, Valeria Cardinali 38, Daniela Cilloni 39, Alessandro Corso 40, Daniele Armiento 41, Luigi Rigacci 42, Elettra Ortu La Barbera 43, Carlo B Gambacorti-Passerini 44, Giuseppe Visani 45, Daniele Vallisa 46, Adriano Venditti 47, Carmine Selleri 48, Annarita Conconi 49, Patrizia Tosi 50, Francesco Lanza 51, Anna Candoni 52, Mauro Krampera 53, Paolo Corradini 54, Francesco Passamonti 55, Francesco Merli 56 | Hematological malignancies, lymphoma, COVID19 | ITA-HEMA-COV |
| 2021 | Hematological oncology | Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience | Fulvio Massaro 1 2, Vincenzo Pavone 3, Piero Maria Stefani 4, Barbara Botto 5, Alessandro Pulsoni 6, Caterina Patti 7, Maria Cantonetti 8, Andrea Visentin 9, Potito Rosario Scalzulli 10, Andrea Rossi 11, Sara Galimberti 12, Michele Cimminiello 13, Guido Gini 14, Maurizio Musso 15, Marco Sorio 16, Annalisa Arcari 17, Vittorio Ruggero Zilioli 18, Mario Luppi 19, Donato Mannina 20, Alberto Fabbri 21, Giuseppe Pietrantuono 22, Ombretta Annibali 23, Agostino Tafuri 24, Eleonora Prete 3, Antonino Mulè 7, Elisa Barbolini 25, Luigi Marcheselli 26, Stefano Luminari 2, Francesco Merli 2 | ASCT, Hodgkin Lymphoma, brentuximab | |
| 2021 | Journal of clinical oncology | Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study | Stefano Luminari 1 2, Martina Manni 1, Sara Galimberti 3, Annibale Versari 4, Alessandra Tucci 5, Carola Boccomini 6, Lucia Farina 7, Jacopo Olivieri 8, Luigi Marcheselli 9, Luca Guerra 10 11, Simone Ferrero 12, Luca Arcaini 13, Federica Cavallo 12, Sofya Kovalchuk 14, Tetiana Skrypets 1 15, Ilaria Del Giudice 16, Stephane Chauvie 17, Caterina Patti 18, Caterina Stelitano 19, Francesca Ricci 20, Antonello Pinto 21, Gloria Margiotta Casaluci 22, Vittorio R Zilioli 23, Anna Merli 24, Marco Ladetto 25 26, Silvia Bolis 27, Vincenzo Pavone 28, Annalisa Chiarenza 29, Annalisa Arcari 30, Antonella Anastasia 5, Alessandra Dondi 9, Donato Mannina 31, Massimo Federico 1, Fondazione Italiana Linfomi | FL | FOLL12 |
| 2021 | Frontiers in Oncology | CNS Prophylaxis: How Far Is Routine Practice From the Guidelines? Focus on a Nationwide Survey by the Fondazione Italiana Linfomi (FIL) | Guido Gini, Alice Di Rocco, Luca Nassi, Annalisa Arcari, Maria Chiara Tisi, Giacomo Loseto, Michela Sampaolo, Massimo Gentile, Ombretta Annibali, Andrés José María Ferreri, Monica Balzarotti | CNS prophylaxis, DLBCL | |
| 2021 | European Journal of Cancer | Primary refractory follicular lymphoma: a poor outcome entity with high risk of transformation to aggressive B cell lymphoma | Sara Alonso-Álvarez 1, Martina Manni 2, Silvia Montoto 3, Clémentine Sarkozy 4, Franck Morschhauser 5, Marielle J Wondergem 6, Attilio Guarini 7, Laura Magnano 8, Miguel Alcoceba 9, Martine Chamuleau 6, Sara Galimberti 10, Maria Gomes da Silva 11, Harald Holte 12, Emanuele Zucca 13, Sandra Lockmer 14, Igor Aurer 15, Luigi Marcheselli 16, Yana Stepanishyna 17, María Dolores Caballero Barrigón 9, Gilles Salles 18, Massimo Federico 2 | Transformation, transformed FL | |
| 2021 | Frontiers in Oncology | Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi | Laura Ballotta 1 2, Pier Luigi Zinzani 3 4, Stefano Pileri 5, Riccardo Bruna 6, Monica Tani 7, Beatrice Casadei 3 4, Valentina Tabanelli 5, Stefano Volpetti 8, Stefano Luminari 9 10, Paolo Corradini 11, Elisa Lucchini 2, Maria Chiara Tisi 12, Michele Merli 13, Alessandro Re 14, Marzia Varettoni 15, Emanuela Anna Pesce 16, Francesco Zaja 1 2 | T-Cell Lymphoma, PTCL | VERT |
| 2020 | Journal of geriatric oncology | Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma, A phase II study by Fondazione Italiana Linfomi | Merli F1, Cavallo F2, Salvi F3, Tucci A4, Musuraca G5, Nassi L6, Merli M7, Tani M8, Gini G9, Ferrari A10, Molinari AL11, Liberati AM12, Conconi A13, Matteucci P14, Bari A15, Scalone R16, Ferrero S2, Zanni M3, Mammi C17, Luminari S18, | DLBCL, unfit | |
| 2020 | Annals of Hematology | Clinical characteristics of interim-PET negative patients with a positive end PET from the prospective HD08-01 FIL study | Luigi Rigacci 1 2, Benedetta Puccini 3, Alessandro Broccoli 4, Manjola Dona 5, Manuel Gotti 6, Andrea Evangelista 7, Armando Santoro 8, Maurizio Bonfichi 6, Alessandro Re 9, Michele Spina 10, Barbara Botto 11, Alessandro Pulsoni 12, Chiara Pagani 9, Caterina Stelitano 13, Flavia Salvi 14, Luca Nassi 15, Lara Mannelli 3, Sofia Kovalchuk 3, Daniela Gioia 7, Pier Luigi Zinzani 4 | PET, Hodgkin lymphoma | HD0801 |
| 2020 | Annals of Hematology | The classic prognostic factors in advanced Hodgkin's lymphoma patients are losing their meaning at the time of Pet-guided treatments | Alessia Bari 1, Raffaella Marcheselli 2, Stefano Sacchi 3, Alessandro Re 4, Chiara Pagani 4, Alessandra Tucci 4, Barbara Botto 5, Umberto Vitolo 5, Anna Lia Molinari 6, Benedetta Puccini 7, Alessandro Pulsoni 8, Armando Santoro 9 10, Monica Tani 11, Luca Nassi 12, Erika Meli 13, Vincenzo Pavone 14, Maurizio Bonfichi 15, Andrea Evangelista 16, Daniela Gioia 2, Alessandro Levis 2, Pierluigi Zinzani 17, Fondazione Italiana Linfomi (Onlus) | PET, Hodgkin lymphoma | |
| 2020 | American Journal of Hematology | Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas | Francine M, Foss Steven M, Horwitz Monica Civallero Monica Bellei Luigi Marcheselli Won Seog Kim Maria E, Cabrera Ivan Dlouhy Arnon Nagler Ranjana H, Advani Emanuela A, Pesce Young‐Hyeh Ko Silvia Montoto Carlos Chiattone Alison Moskowitz Michele Spina Marina Cesaretti Irene Biasoli Massimo Federico | PTCL, hepatosplenic, enteropathy associated, peripheral gamma delta T cell lymphomas | T-Cell Project |
| 2020 | Radiation Oncology | Fondazione Italiana Linfomi (FIL) expert consensus on the use of intensity-modulated and image-guided radiotherapy for Hodgkin's lymphoma involving the mediastinum | Filippi AR1, Meregalli S2, DI Russo A3, Levis M4, Ciammella P5, Buglione M6, Guerini AE6, De Marco G7, De Sanctis V8, Vagge S9, Ricardi U4, Simontacchi G10; Fondazione Italiana Linfomi (FIL) Radiotherapy Committee, | RT, Hodgkin lymphoma, mediastinum | |
| 2020 | The Lancet Haematology | Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project | Christopher P Fox 1, Monica Civallero 2, Young-Hyeh Ko 3, Martina Manni 2, Tetiana Skrypets 2, Stefano Pileri 4, Seok Jin Kim 5, Maria Elena Cabrera 6, Andrei R Shustov 7, Carlos S Chiattone 8, Steven M Horwitz 9, Ivan Dlouhy 10, Michele Spina 11, Felicitas Hitz 12, Silvia Montoto 13, Arnon Nagler 14, Virginia Martinez 15, Carmino A De Souza 16, Ruben Fernandez-Alvarez 17, Veronika Ballova 18, Raul Gabús 19, Giorgio Inghirami 20, Massimo Federico 2, Won Seog Kim 21 | Extranodal Natural Killer T-Cell lymphoma, PTCL | T-Cell Project |
| 2020 | Haematologica | KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study | Simone Ferrero 1 2, Davide Rossi 3 4, Andrea Rinaldi 4, Alessio Bruscaggin 4, Valeria Spina 4, Christian W Eskelund 5 6, Andrea Evangelista 7, Riccardo Moia 8, Ivo Kwee 4 9 10, Christina Dahl 11, Alice Di Rocco 12, Vittorio Stefoni 13, Fary Diop 8, Chiara Favini 8, Paola Ghione 14, Abdurraouf Mokhtar Mahmoud 8, Mattia Schipani 8, Arne Kolstad 15, Daniela Barbero 14, Domenico Novero 16, Marco Paulli 17, Alberto Zamò 18 19, Mats Jerkeman 20, Maria Gomes da Silva 21, Armando Santoro 22, Annalia Molinari 23, Andres Ferreri 24, Kirsten Grønbæk 5 6, Andrea Piccin 25, Sergio Cortelazzo 26, Francesco Bertoni 4, Marco Ladetto 27, Gianluca Gaidano 8 | MCL | MCL0208 |
| 2020 | Hematological oncology | Nonpeghylated liposomal doxorubicin combination regimen (R-COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity | Luigi Rigacci 1 2, Ombretta Annibali 3, Sofya Kovalchuk 2, Elisabetta Bonifacio 4, Francesca Pregnolato 5, Francesco Angrilli 6, Umberto Vitolo 7, Samantha Pozzi 8, Serena Broggi 4, Stefano Luminari 8 9, Francesco Merli 9, Michele Spina 10, Silvia Bolis 11, Gloria Margiotta-Casaluci 12, Rosario Scalzulli 13, Christina Cox 14, Angela Maria Mamusa 15, Armando Santoro 16, Pier Luigi Zinzani 17, Samantha Ferrari 18, Guido Gini 19, Maria Luigia Vigliotti 20, Antonino Mulè 21, Leonardo Flenghi 4, Fondazione Italiana Linfomi (FIL) | Non-Hodgkin Lymphoma | R-COMP |
| 2020 | The Lancet Haematology | Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study | Francesco Passamonti 1, Chiara Cattaneo 2, Luca Arcaini 3, Riccardo Bruna 4, Michele Cavo 5, Francesco Merli 6, Emanuele Angelucci 7, Mauro Krampera 8, Roberto Cairoli 9, Matteo Giovanni Della Porta 10, Nicola Fracchiolla 11, Marco Ladetto 12, Carlo Gambacorti Passerini 13, Marco Salvini 14, Monia Marchetti 12, Roberto Lemoli 15, Alfredo Molteni 16, Alessandro Busca 17, Antonio Cuneo 18, Alessandra Romano 19, Nicola Giuliani 20, Sara Galimberti 21, Alessandro Corso 22, Alessandro Morotti 23, Brunangelo Falini 24, Atto Billio 25, Filippo Gherlinzoni 26, Giuseppe Visani 27, Maria Chiara Tisi 28, Agostino Tafuri 29, Patrizia Tosi 30, Francesco Lanza 31, Massimo Massaia 32, Mauro Turrini 33, Felicetto Ferrara 34, Carmela Gurrieri 35, Daniele Vallisa 36, Maurizio Martelli 37, Enrico Derenzini 38, Attilio Guarini 39, Annarita Conconi 40, Annarosa Cuccaro 41, Laura Cudillo 42, Domenico Russo 43, Fabrizio Ciambelli 44, Anna Maria Scattolin 45, Mario Luppi 46, Carmine Selleri 47, Elettra Ortu La Barbera 48, Celestino Ferrandina 49, Nicola Di Renzo 50, Attilio Olivieri 51, Monica Bocchia 52, Massimo Gentile 53, Francesco Marchesi 54, Pellegrino Musto 55, Augusto Bramante Federici 56, Anna Candoni 57, Adriano Venditti 58, Carmen Fava 23, Antonio Pinto 59, Piero Galieni 60, Luigi Rigacci 61, Daniele Armiento 62, Fabrizio Pane 63, Margherita Oberti 2, Patrizia Zappasodi 64, Carlo Visco 8, Matteo Franchi 65, Paolo Antonio Grossi 14, Lorenza Bertù 14, Giovanni Corrao 65, Livio Pagano 66, Paolo Corradini 67, ITA-HEMA-COV Investigators | Hematological malignancies, lymphoma, COVID19 | ITA-HEMA-COV |
| 2020 | Hematological oncology | Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma | Irene Della Starza 1, Lucia Anna De Novi 1, Marzia Cavalli 1, Noemi Novelli 1, Roberta Soscia 1, Elisa Genuardi 2, Barbara Mantoan 2, Daniela Drandi 2, Martina Ferrante 2, Luigia Monitillo 2, Daniela Barbero 2, Elena Ciabatti 3, Susanna Grassi 4, Riccardo Bomben 5, Massimo Degan 5, Valter Gattei 5, Sara Galimberti 3, Alice Di Rocco 1, Maurizio Martelli 1, Sergio Cortelazzo 6, Anna Guarini 7, Robin Foà 1, Marco Ladetto 8, Simone Ferrero 2 9, Ilaria Del Giudice 1, Fondazione Italiana Linfomi (FIL) MRD Network | MRD, MCL | |
| 2020 | Haematologica | Brentuximab Vedotin In The Treatment Of Elderly Hodgkin Lymphoma Patients At First Relapse Or With Primary Refractory Disease: A Phase 2 Study Of FIL ONLUS | Stefoni V1, Marangon M1, Re A2, Lleshi A3, Bonfichi M4, Pinto A5, Bianchetti N2, Pellegrini C6, Argnani L1, Zinzani PL7, | Elderly, Hodgkin Lymphoma, brentuximab | |
| 2020 | Journal of clinical oncology | Consolidation Radiotherapy Could Be Safely Omitted in Advanced Hodgkin Lymphoma With Large Nodal Mass in Complete Metabolic Response After ABVD: Final Analysis of the Randomized GITIL/FIL HD0607 Trial | Andrea Gallamini 1, Andrea Rossi 2, Caterina Patti 3, Marco Picardi 4, Alessandra Romano 5, Maria Cantonetti 6, Sara Oppi 7, Simonetta Viviani 8, Silvia Bolis 9, Livio Trentin 10, Guido Gini 11, Roberta Battistini 12, Stephane Chauvie 13, Roberto Sorasio 14, Chiara Pavoni 2, Roberta Zanotti 15, Michele Cimminiello 16, Corrado Schiavotto 17, Piera Viero 18, Antonino Mulé 3, Federico Fallanca 19, Umberto Ficola 20, Corrado Tarella 21 22, Luca Guerra 23, Alessandro Rambaldi 2 24 | RT, PET, Hodgkin lymphoma | HD0607 (GITIL/FIL) |
| 2020 | Bone Marrow Transplantation | Multidimensional geriatric assessment for elderly hematological patients (≥60 years) submitted to allogeneic stem cell transplantation. A French-Italian 10-year experience on 228 patients | Nicola Polverelli 1, Paolo Tura 2 3, Giorgia Battipaglia 3, Michele Malagola 2, Simona Bernardi 2 4, Lisa Gandolfi 2, Tatiana Zollner 2, Camilla Zanaglio 2 4, Mirko Farina 2, Enrico Morello 2, Alessandro Turra 2, Mohamad Mohty # 3, Domenico Russo # 2 | CGA, Elderly, Allo-transplantation | French-Italian study |
| 2020 | Bone Marrow Transplantation | Stem cell mobilization after bendamustine in indolent lymphomas: a multicenter study on behalf of the Fondazione Italiana Linfomi | Michele Merli 1, Stefano Luminari 2 3, Lucia Farina 4, Federica Cocito 5, Irene Defrancesco 6, Guido Gini 7, Annalisa Arcari 8, Greta Scapinello 9, Massimo Gentile 10, Maria Goldaniga 11, Giacomo Loseto 12, Emanuele Cencini 13, Antonino Greco 14, Anna Lia Molinari 15, Andrea Ferrario 16, Benedetta Bianchi 16, Barbara Mora 16, Lorenza Bertù 16, Vincenzo Saturni 17, Fabio Bergamini 18, Nicole Fabbri 18, Francesca Gaia Rossi 11, Silvia Bolis 5, Francesco Passamonti 16, Luca Arcaini 6 18 | Indolent non-Hodgkin Lymphoma, stem cell mobilization, ASCT | |
| 2019 | British journal of haematology | Outcome of transformed follicular lymphoma worsens according to the timing of transformation and to the number of previous therapies, A retrospective multicenter study on behalf of Fondazione Italiana Linfomi (FIL) | Rusconi C1, Anastasia A2, Chiarenza A3, Marcheselli L4, Cavallo F5, Rattotti S6, Botto B7, Ferrari A8, Nassi L9, Pagani C2, Meli E1, Arcaini L6, Federico M4, Rossi G2; Fondazione Italiana Linfomi (FIL), | Transformation, transformed FL | |
| 2019 | Journal of the European Academy of Dermatology and Venereology (JEADV) | Bexarotene as maintenance treatment after other than skin-directed therapy in advanced stage mycosis fungoides: a pilot study | Pileri A1,2, Fava P3, Fuligni F4, Gunnella S2, Guglielmo A1, Astrua C3, Grandi V2, Simontacchi G5, Patrizi A1, Quaglino P3, Pimpinelli N2; Lymphoma Italian Foundation (Fondazione Italiana Linfomi-FIL) - Cutaneous Lymphoma Task Force (Commissione Linfomi Cutanei), | Mycosis Fungoides | |
| 2019 | British journal of haematology | Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib | Michael Mian 1 2, Norbert Pescosta 1, Stefania Badiali 3, Paola Cristina Cappelletto 4, Luigi Marcheselli 3, Stefano Luminari 5, Francesca Patriarca 6, Renato Zambello 7, Anna Pascarella 8, Giuseppe Tagariello 9, Alessandra Marabese 1, Patrizia Mondello 10 11 12, Atto Billio 1, Sergio Cortelazzo 13 | Multiple Mieloma, MM | |
| 2019 | Giornale italiano di dermatologia e venereologia | Primary cutaneous CD8+ CD30+ lymphoproliferative disorder in a patient with acquired CD4 immunodeficiency | Pileri A1,2, Gunnella S3, Grandi V3, Maio V4, Santucci M4, Pimpinelli N3; Lymphoma Italian Foundation (Fondazione Italiana Linfomi, FIL) - Cutaneous Lymphoma Task Force (Commissione Linfomi Cutanei), | Extranodal, Primary cutaneous | |
| 2019 | British journal of haematology | Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death | Carlo Visco 1, Maria C Tisi 1, Andrea Evangelista 2, Alice Di Rocco 3, Anna-Katharina Zoellner 4, Vittorio R Zilioli 5, Stefan Hohaus 6, Roberta Sciarra 7, Alessandro Re 8, Cristina Tecchio 9, Annalisa Chiappella 10, Lucia Morello 11, Guido Gini 12, Luca Nassi 13, Tommasina Perrone 14, Anna L Molinari 15, Alberto Fabbri 16, Maria C Cox 17, Erica Finolezzi 18, Simone Ferrero 19, Benedetta Puccini 20, Isabel Alvarez De Celis 21, Annalisa Arcari 22, Dario Marino 23, Michele Merli 24, Francesco Piazza 25, Massimo Gentile 26, Matteo Pelosini 27, Giacomo Loseto 28, Olivier Hermine 29, Martin Dreyling 4, Marco Ruggeri 1, Maurizio Martelli 3, Eva Hoster 4, Umberto Vitolo 10, Fondazione Italiana Linfomi and the Mantle Cell Lymphoma Network | MCL | |
| 2019 | Leukemia & Lymphoma | Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL), | Salvi F1, Luminari S2,3, Tucci A4, Massidda S5, Liberati AM6, Stelitano C7, Zanni M1, Re A4, Centurioni R8, Freilone R9, Musuraca G10, Nassi L11, Patti C12, Arcari A13, Tani M14, Pulsoni A15, Pavone V16, Volpetti S17, Peli A4, Evangelista A18, Spina M19, Ladetto M1, Merli F2, | Elderly, Hodgkin Lymphoma | MBVD |
| 2019 | Blood | Early Progression As a Predictor of Survival in Marginal Zone Lymphomas: An Analysis from the FIL-NF10 Study | Luminari S1,2, Merli M3,4, Rattotti S5,6, Tarantino V7,8, Marcheselli L9, Cavallo F10,11, Varettoni M12, Bianchi B13, Merli F14, Tedeschi A15,16, Cabras G17,18, Re F19, Visco C20, Delamain MT21,22, Cencini E23, Spina M24, Ferrero S25,11, Ferrari A26, Deodato M27,16, Mannina D28,29, Annibali O30,31, Rago A32,33, Orsucci L34, Defrancesco I35, Frigeni M12,36, Cesaretti M37, Arcaini L38,39, | Marginal Zone Lymphoma, MZL | NF10 |
| 2019 | Hematological oncology | Minimal residual disease (MRD) in non‐Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network | Della Starza I1, Cavalli M1, De Novi LA1, Genuardi E2, Mantoan B2, Drandi D2, Barbero D2, Ciabatti E3, Grassi S4, Gazzola A5, Mannu C5, Agostinelli C5, Piccaluga PP5, Bomben R6, Degan M6, Gattei V6, Guarini A7, Foà R1, Galimberti S3, Ladetto M8, Ferrero S2, Del Giudice I1; Fondazione Italiana Linfomi (FIL) MRD Network, | MRD, non-Hodgkin lymphoma | |
| 2019 | JCO Clinical Cancer Informatics | Applying Data Warehousing to a Phase III Clinical Trial From the Fondazione Italiana Linfomi Ensures Superior Data Quality and Improved Assessment of Clinical Outcomes | Zaccaria GM, Ferrero S, Rosati S, Ghislieri M, Genuardi E, Evangelista A, Sandrone R, Castagneri C, Barbero D, Lo Schirico M, Arcaini L, Molinari AL, Ballerini F, Ferreri A, Omedè P, Zamò A, Balestra G, Boccadoro M, Cortelazzo S, Ladetto M, | Data Warehousing | MCL0208 |
| 2019 | Hemasphere | MYC Rearranged Aggressive B-Cell Lymphomas: a report on 100 patients of the Fondazione Italiana Linfomi (FIL) | Maria Chiara Tisi,1,2 Simone Ferrero,3 Irene Dogliotti,3 Cristina Tecchio,4 Giuseppe Carli,1 Mattia Novo,5 Piero Maria Stefani,6 Sara Rattotti,7 Monica Balzarotti,8 Dario Marino,9 Matteo Pelosini,10 Alessandra Romano,11 Leonardo Flenghi,12 Vittorio Ruggero Zilioli,13 Teresa Calimeri,14 Arianna Di Napoli,15 Manuela Zanni,16 Erica Finolezzi,17 Federico Mosna,6,18 Guido Gini,19 Giovanna Mansueto,20 Alice Di Rocco,21 Gabriella Tomei,22 Nicola Sgherza,23 Jacopo Olivieri,24,25 Luca Nassi,26 Francesco Piazza,27 Angelo Fama,28 Antonio Greco,29 Margherita Giannoccaro,30 Anna Maria Mazzone,31 Carlo Visco,32 Giacomo Loseto,33 and Francesco Zaja25,34, on behalf of the Fondazione Italiana Linfomi Postgraduate Master course | Aggressive B-cell lymphoma | |
| 2019 | Blood Cancer J | First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi, | Broccoli A1, Argnani L1, Botto B2, Corradini P3, Pinto A4, Re A5, Vitolo U2, Fanti S6, Stefoni V1, Zinzani PL7; Fondazione Italiana Linfomi ONLUS, | Hodgkin Lymphoma | |
| 2019 | The Lancet | Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial | Poeschel V1, Held G2, Ziepert M3, Witzens-Harig M4, Holte H5, Thurner L6, Borchmann P7, Viardot A8, Soekler M9, Keller U10, Schmidt C11, Truemper L12, Mahlberg R13, Marks R14, Hoeffkes HG15, Metzner B16, Dierlamm J17, Frickhofen N18, Haenel M19, Neubauer A20, Kneba M21, Merli F22, Tucci A23, de Nully Brown P24, Federico M25, Lengfelder E26, di Rocco A27, Trappe R28, Rosenwald A29, Berdel C30, Maisenhoelder M31, Shpilberg O32, Amam J6, Christofyllakis K6, Hartmann F6, Murawski N6, Stilgenbauer S6, Nickelsen M33, Wulf G12, Glass B33, Schmitz N33, Altmann B3, Loeffler M3, Pfreundschuh M6; FLYER Trial Investigators; German Lymphoma Alliance, | DLBCL | FLYER |
| 2018 | Journal of clinical oncology | Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-TermResults of the GITIL/FIL HD 0607 Trial | Gallamini A1, Tarella C1, Viviani S1, Rossi A1, Patti C1, Mulé A1, Picardi M1, Romano A1, Cantonetti M1, La Nasa G1, Trentin L1, Bolis S1, Rapezzi D1, Battistini R1, Gottardi D1, Gavarotti P1, Corradini P1, Cimminiello M1, Schiavotto C1, Parvis G1, Zanotti R1, Gini G1, Ferreri AJM1, Viero P1, Miglino M1, Billio A1, Avigdor A1, Biggi A1, Fallanca F1, Ficola U1, Gregianin M1, Chiaravalloti A1, Prosperini G1, Bergesio F1, Chauvie S1, Pavoni C1, Gianni AM1, Rambaldi A1, | Hodgkin Lymphoma | HD0607 (GITIL/FIL) |
| 2018 | Haematologica | A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial, | Bomben R1, Ferrero S2,3, D'Agaro T4, Dal Bo M4, Re A5, Evangelista A6, Carella AM7, Zamò A8, Vitolo U3, Omedè P3, Rusconi C9, Arcaini L10, Rigacci L11, Luminari S12,13, Piccin A14, Liu D15, Wiestner A15, Gaidano G16, Cortelazzo S17, Ladetto M2,18, Gattei V4, | MCL | MCL0208 |
| 2018 | Journal of the European Academy of Dermatology and Venereology (JEADV) | Standardization of regimens in Narrowband UVB and PUVA in early stage mycosis fungoides: position paper from the Italian Task Force for Cutaneous Lymphomas | Grandi V1, Fava P2, Rupoli S3, Alberti Violetti S4, Canafoglia L3, Quaglino P2, Berti E4, Pimpinelli N1; Cutaneous Lymphoma Task Force (Commissione Linfomi Cutanei) of Lymphoma Italian Foundation (Fondazione Italiana Linfomi, FIL), | Mycosis Fungoides | |
| 2018 | Biol Blood Marrow Transplant | A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi | Olivieri J1, Mosna F2, Pelosini M3, Fama A4, Rattotti S5, Giannoccaro M6, Carli G7, Tisi MC7, Ferrero S8, Sgherza N9, Mazzone AM10, Marino D11, Calimeri T12, Loseto G13, Saraceni F14, Tomei G15, Sica S16, Perali G17, Codeluppi K4, Billio A2, Olivieri A18, Orciuolo E3, Matera R6, Stefani PM19, Borghero C7, Ghione P8, Cascavilla N9, Lanza F14, Chiusolo P16, Finotto S11, Federici I18, Gherlinzoni F19, Centurioni R20, Fanin R21, Zaja F21; Fondazione Italiana LinfomiPostgraduate Master Course, | ASCT | BEAM vs FEAM |
| 2018 | Blood | Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study | Cottereau AS, Versari A, Luminari S, Dupuis J, Chartier L, Casasnovas RO, Berriolo-Riedinger A, Menga M, Haioun C, Tilly H, Tarantino V, Federico M, Salles G, Trotman J, Meignan M, | PET, FL | Lysa/FIL study |
| 2018 | British journal of haematology | High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO | Avivi I1, Arcaini L2, Ferretti VV3, Boumendil A4, Finel H4, Milone G5, Zaja F6, Liliana D7, Musso M8, Didier B9, Bachy E10, Wattad M11, Nicolas-Virelizier E12, Gramatzki M13,14, Bourhis JH15, Caillot D16, Haenel A17, Held G18,19, Thieblemont C20, Jindra P21, Pohlreich D22, Guilhot F23, Kroschinsky F24, Wahlin B25, Scheid C26, Ifrah N27, Berthou C28, Dreger P4,29, Montoto S30, Conconi A31, | Marginal Zone Lymphoma, MZL | EBMT/FIL/GITMO study |
| 2018 | Blood Cancer J | CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies | Ayed AO, Chiappella A, Pederson L, Laplant BR, Congiu AG, Gaidano G, Spina M, Re A, Cavallo F, Musuraca G, Macon WR, Witzig T, Vitolo U, Nowakowski GS | Extranodal, Primary CNS, DLBCL | R2-CHOP |
| 2018 | Blood | Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma | Luca Ceriani 1, Lisa Milan 1, Maurizio Martelli 2, Andrés J M Ferreri 3, Luciano Cascione 4, Pier Luigi Zinzani 5, Alice Di Rocco 2, Annarita Conconi 6, Anastasios Stathis 7, Franco Cavalli 4, Monica Bellei 8, Kelly Cozens 9, Elena Porro 4, Luca Giovanella 1, Peter W Johnson 10, Emanuele Zucca 4 7 11 | PET, PMBCL | IELSG26 |
| 2018 | Lancet Hematology | Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis | Massimo Federico 1, María Dolores Caballero Barrigón 2, Luigi Marcheselli 3, Vittoria Tarantino 4, Martina Manni 4, Clementine Sarkozy 5, Sara Alonso-Álvarez 6, Marielle Wondergem 7, Guillaume Cartron 8, Armando Lopez-Guillermo 9, Djamila Issa 10, Franck Morschhauser 11, Miguel Alcoceba 2, Eva Kimby 12, Chiara Rusconi 13, Martine Chamuleau 7, Harald Holte 14, Sandra Lockmer 12, Silvia Montoto 15, Maria Gomes da Silva 16, Igor Aurer 17, Emanuele Zucca 18, Ewa Paszkiewicz-Kozik 19, Carla Minoia 20, Tetiana Skrypets 4, Yngvild Nuvin Blaker 14, Gilles Salles 5, Bertrand Coiffier 5, Aristotle Consortium | FL | Aristotle Consortium study |
| 2018 | Haematologica | Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi | Sergio Storti 1, Michele Spina 2, Emanuela Anna Pesce 3, Flavia Salvi 4, Michele Merli 5, Alessia Ruffini 6, Giuseppina Cabras 7, Annalisa Chiappella 8, Emanuele Angelucci 9, Alberto Fabbri 10, Anna Marina Liberati 11, Monica Tani 12, Gerardo Musuraca 13, Annalia Molinari 14, Maria Pia Petrilli 1, Carmela Palladino 4, Rosanna Ciancia 2, Andrea Ferrario 5, Cristiana Gasbarrino 1, Federico Monaco 4, Vincenzo Fraticelli 1, Annalisa De Vellis 1, Francesco Merli 15, Stefano Luminari 16 17 | Elderly, DLBCL, frail | |
| 2018 | Giornale italiano di dermatologia e venereologia | Real-life use of phototherapy in early-stage mycosis fungoides from the Cutaneous Lymphoma Commission of the Italian Lymphoma Foundation: results of a web-based survey | Grandi V, Fava P, Rupoli S, Alberti Violetti S, Canafoglia L, Berti E, Quaglino P, Pimpinelli N | Mycosis Fungoides | |
| 2018 | British journal of haematology | Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study | Iannitto E1, Bellei M2, Amorim S3, Ferreri AJM4, Marcheselli L2, Cesaretti M2, Haioun C5, Mancuso S1, Bouabdallah K6, Gressin R7,8, Tripodo C9, Traverse-Glehen A10, Baseggio L11, Zupo S12, Stelitano C13, Castagnari B14, Patti C15, Alvarez I16, Liberati AM17, Merli M18, Gini G19, Cabras MG20, Dupuis J21, Tessoulin B22, Perrot A23, Re F24, Palombi F25, Gulino A9, Zucca E26, Federico M27, Thieblemont C28, | SMZL, Splenic Marginal Zone Lymphonma | |
| 2018 | Blood Cancer J | Lenalidomide plus R-CHOP21 in newly diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): long-term follow up results from a combined analysis from two phase 2 trials | A, Castellino1,2*, A, Chiappella1*, B,R, LaPlant2, L,D, Pederson2, G, Gaidano3, W,R, Macon2, G, Inghirami4, C,B, Reeder5, A, Tucci6, R,L, King2, A, Congiu7, J,M, Foran8, V, Pavone9, C,E, Rivera8, M, Spina10, S,M, Ansell2, F, Cavallo1, A,L, Molinari11, Giovannino Ciccone12, T,M, Habermann2, T,E, Witzig2, U, Vitolo1, and G,S, Nowakowski2 | DLBCL | |
| 2018 | Am J Hematol | Rituximab, bendamustine and cytarabine (R-BAC) in patients with relapsed-refractory aggressive B-cell lymphoma | Maria Chiara Tisi 1, Rossella Paolini 2, Francesco Piazza 3, Erika Ravelli 4, Cristina Tecchio 5, Roberto Sartori 6, Barbara Famengo 7, Emanuele Stefano Giovanni D'Amore 7, Giuseppe Carli 1, Omar Perbellini 1, Eros Di Bona 1, Marco Ruggeri 1, Carlo Visco 1 | Aggressive B-cell lymphoma, MCL | R-BAC |
| 2018 | Annals of Oncology | Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue | S, Ciavarella1,*, M, C, Vegliante1,*, M,Fabbri2,*, S, De Summa3, F, Melle2, G, Motta2, V, De Iuliis4, G, Opinto5, A, Enjuanes6, S, Rega7, A, Gulino8, C, Agostinelli9, A, Scattone7, S, Tommasi3, A, Mangia5, F, Mele7, G, Simone7, A, F, Zito7, G, Ingravallo10, U, Vitolo11, A, Chiappella11, C, Tarella12, A, M, Gianni12, A, Rambaldi13, P, L, Zinzani9, B, Casadei9, E, Derenzini12, G, Loseto1, A, Pileri9, V, Tabanelli2, S, Fiori2, A, Rivas-Delgado14, A, López-Guillermo14, T, Venesio15, A, Sapino15, E, Campo16, C, Tripodo8, A, Guarini1,† and S, A, Pileri2, † | DLBCL | RHDS0305, DLBCL |
| 2018 | Leukemia Lymphoma | Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi | Francesco Zaja 1, Flavia Salvi 2, Maura Rossi 3, Elena Sabattini 4, Andrea Evangelista 4, Giovannino Ciccone 5, Emanuele Angelucci 6, Gianluca Gaidano 7, Manuela Zanni 7, Marco Ladetto 2, Annalisa Chiappella 8, Umberto Vitolo 8, Pier Luigi Zinzani 9, Catello Califano 10, Alessandra Tucci 11, Caterina Patti 12, Stefano A Pileri 13, Valentina Lenti 14, Pier Paolo Piccaluga 3, Federica Cavallo 15, Stefano Volpetti 16, Giulia Perali 16, Sarit Assouline 17, Koren Kathleen Mann 18, Ryan Morin 19, Miguel Alcaide 19, Kevin Bushell 19, Renato Fanin 1, Alessandro Levis 14 | DLBCL | Panobinostat |
| 2017 | Hematological oncology | Training improves the interobserver agreement of the expert positron emission tomography review panel in primary mediastinal B-cell lymphoma: interim analysis in the ongoing International Extranodal Lymphoma Study Group-37 study, | Ceriani L, Barrington S, Biggi A, Malkowski B, Metser U, Versari A, Martelli M, Davies A, Johnson PW, Zucca E, Chauvie S, | PET, PMBCL | IELSG37 |
| 2017 | International Journal of Radiation Oncology Biology Physics | Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma | Ceriani L1, Martelli M2, Gospodarowicz MK3, Ricardi U4, Ferreri AJ5, Chiappella A6, Stelitano C7, Balzarotti M8, Cabrera ME9, Cunningham D10, Guarini A11, Zinzani PL12, Giovanella L13, Johnson PW14, Zucca E15, | PET, PMBCL | IELSG26 |
| 2017 | The Lancet Haematology | Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi | Carlo Visco 1, Annalisa Chiappella 2, Luca Nassi 3, Caterina Patti 4, Simone Ferrero 5, Daniela Barbero 5, Andrea Evangelista 6, Michele Spina 7, Annalia Molinari 8, Luigi Rigacci 9, Monica Tani 10, Alice Di Rocco 11, Graziella Pinotti 12, Alberto Fabbri 13, Renato Zambello 14, Silvia Finotto 15, Manuel Gotti 16, Angelo M Carella 17, Flavia Salvi 18, Stefano A Pileri 19, Marco Ladetto 18, Giovannino Ciccone 6, Gianluca Gaidano 3, Marco Ruggeri 20, Maurizio Martelli 11, Umberto Vitolo 2 | Elderly, MCL | |
| 2017 | Hematological oncology | Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity, Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi | Luminari S, Viel E, Ferreri AJM, Zaja F, Chimienti E, Musuraca G, Tucci A, Balzarotti M, Tani M, Salvi F, Pesce EA, Ferrari A, Liberati AM, Spadea A, Marino D, Bruno-Ventre M, Volpetti S, Bottelli C, Ravaioli E, Merli F, Spina M, | DLBCL, cardiac comorbidity | HEART01 |
| 2017 | Thrombosis and haemostasis | Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas, A pooled-data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL) | Santi RM, Ceccarelli M, Bernocco E, Monagheddu C, Evangelista A, Valeri F, Monaco F, Vitolo U, Cortelazzo S, Cabras MG, Spina M, Baldini L, Boccomini C, Chiappella A, Bari A, Luminari S, Visco C, Calabrese M, Limberti G, Levis A, Contino L, Ciccone G, Ladetto M, | Venous tromboembolism, VTE | |
| 2017 | Haematologica | Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi | Francesco Zaja 1, Simone Ferrero 2, Caterina Stelitano 3, Angela Ferrari 4, Flavia Salvi 5, Annalisa Arcari 6, Gerardo Musuraca 7, Barbara Botto 8, Michele Spina 9, Claudia Cellini 10, Caterina Patti 11, Anna M Liberati 12, Claudia Minotto 13, Stefano A Pileri 14, Manuela Ceccarelli 15, Stefano Volpetti 16, Antonella Ferranti 17, Daniela Drandi 2, Elisa Montechiarello 3, Marco Ladetto 18, James Carmichael 19, Renato Fanin 16 | MCL | R2-B |
| 2017 | Journal of clinical oncology | Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial | André MPE, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M, Casasnovas O, Brice P, van der Maazen R, Re A, Edeline V, Fermé C, van Imhoff G, Merli F, Bouabdallah R, Sebban C, Specht L, Stamatoullas A, Delarue R, Fiaccadori V, Bellei M, Raveloarivahy T, Versari A, Hutchings M, Meignan M, Raemaekers J, | PET, Hodgkin Lymphoma | EORTC/LySA/FIL 20051 - H10 |
| 2017 | Journal of clinical oncology | Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy, | Zucca E, Conconi A, Martinelli G, Bouabdallah R, Tucci A, Vitolo U, Martelli M, Pettengell R, Salles G, Sebban C, Guillermo AL, Pinotti G, Devizzi L, Morschhauser F, Tilly H, Torri V, Hohaus S, Ferreri AJM, Zachée P, Bosly A, Haioun C, Stelitano C, Bellei M, Ponzoni M, Moreau A, Jack A, Campo E, Mazzucchelli L, Cavalli F, Johnson P, Thieblemont C, | Extranodal, MALT | IELSG19 |
| 2017 | Annals of Hematology | Role of bone marrow biopsy in staging of patients with classical Hodgkin's lymphoma undergoing positron emission tomography/computed tomography | B Puccini 1, L Nassi 2, C Minoia 3, S Volpetti 4, R Ciancia 5, P C Riccomagno 6, A Di Rocco 7, A Mulè 8, C Toldo 9, M C Sassone 10, R Guariglia 11, C Filì 12, E Finolezzi 13, S Falorio 13, S Zanon 14, A Furlan 15, G Doa 16, F Zaja 4, Fondazione Italiana Linfomi Postgraduate Master course | PET, Hodgkin Lymphoma, bone marrow biopsy | |
| 2017 | Expert review of hematology | Is now the time for molecular driven therapy for diffuse large B-cell lymphoma? | Di Rocco A, De Angelis F, Ansuinelli M, Foà R, Martelli M | DLBCL, molecular-driven therapy | |
| 2017 | British journal of haematology | Diffuse large B cell lymphoma cell of origin by digital expression profiling in the REAL07 Phase 1-2 study | Cascione L1,2,3, Rinaldi A1, Chiappella A4, Kwee I1,3,5, Ciccone G6, Altenbuchinger M7, Kohler C7, Vitolo U4, Inghirami G8,9,10, Bertoni F1,2, | DLBCL | REAL07 |
| 2017 | British journal of haematology | Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study | Ceriani L, Martelli M, Conconi A, Zinzani PL, Ferreri AJM, Botto B, Stelitano C, Gotti M, Cabras MG, Rigacci L, Giovanella L, Zucca E, Johnson PWM, | PET, PMBCL | IELSG26 |
| 2017 | The Lancet Oncology | Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study | Annalisa Chiappella 1, Maurizio Martelli 2, Emanuele Angelucci 3, Ercole Brusamolino 4, Andrea Evangelista 5, Angelo Michele Carella 6, Caterina Stelitano 7, Giuseppe Rossi 8, Monica Balzarotti 9, Francesco Merli 10, Gianluca Gaidano 11, Vincenzo Pavone 12, Luigi Rigacci 13, Francesco Zaja 14, Alfonso D'Arco 15, Nicola Cascavilla 16, Eleonora Russo 2, Alessia Castellino 17, Manuel Gotti 4, Angela Giovanna Congiu 6, Maria Giuseppina Cabras 3, Alessandra Tucci 8, Claudio Agostinelli 18, Giovannino Ciccone 5, Stefano A Pileri 19, Umberto Vitolo 17 | DLBCL | DLCL04 |
| 2017 | Journal of clinical oncology | Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma | Vitolo U1, Trněný M1, Belada D1, Burke JM1, Carella AM1, Chua N1, Abrisqueta P1, Demeter J1, Flinn I1, Hong X1, Kim WS1, Pinto A1, Shi YK1, Tatsumi Y1, Oestergaard MZ1, Wenger M1, Fingerle-Rowson G1, Catalani O1, Nielsen T1, Martelli M1, Sehn LH1, | DLBCL | GOYA |
| 2017 | Blood | Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial | Pier Luigi Zinzani,1 Cinzia Pellegrini,1 Annalisa Chiappella,2 Alice Di Rocco,3 Flavia Salvi,4 Maria Giuseppina Cabras,5 Lisa Argnani,1 and Vittorio Stefoni1 | Extranodal, PMBCL | SGN01 |
| 2017 | International Journal of Laboratory Hematology | Ficoll-hypaque separation vs whole blood lysis: Comparison of efficiency and impact on minimal residual disease analysis | Genuardi E, Barbero D, Dogliotti I, Mantoan B, Drandi D, Gambella M, Zaccaria GM, Monitillo L, Della Starza I, Cavalli M, De Novi LA, Ciabatti E, Grassi S, Gazzola A, Mannu C, Del Giudice I, Galimberti S, Agostinelli C, Piccaluga PP, Ladetto M, Ferrero S; Fondazione Italiana Linfomi (FIL) MRD Network, | MRD | |
| 2017 | The Lancet Haematology | Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial | Andrés J, M, Ferreri, MD1, Kate Cwynarski, MD2, Elisa Pulczynski, MD3, Christopher P, Fox, MD4, Elisabeth Schorb, MD5, Paul La Rosée, MD6§, Mascha Binder, MD7§, Alberto Fabbri, MD8, Valter Torri, MD9, Eleonora Minacapelli, MD10, Monica Falautano, MD10, Fiorella Ilariucci, MD11, Achille Ambrosetti, MD12§, Alexander Roth, MD13, Claire Hemmaway, MD14, Peter Johnson, MD15§, Kim M, Linton, PhD16, Tobias Pukrop, MD17§, Jette Sønderskov Gørløv, PhD18, Monica Balzarotti, MD19, Georg Hess, MD20, Ulrich Keller, MD21§, Stephan Stilgenbauer, MD22§, Jens Panse, MD23, Alessandra Tucci, MD24, Lorella Orsucci, MD25, Francesco Pisani, MD26, Alessandro Levis, MD27, Stefan W, Krause, MD28§, Hans J, Schmoll, MD29, Bernd Hertenstein, MD30, Mathias Rummel, MD31, Jeffery Smith, MD32, Michael Pfreundschuh, MD33, Giuseppina Cabras, MD34, Francesco Angrilli, MD35, Maurilio Ponzoni, MD36§, Martina Deckert, MD37§, Letterio S, Politi, MD38, Jürgen Finke, MD5, Michele Reni, MD39, Franco Cavalli, MD40§, Emanuele Zucca, MD40, Gerald Illerhaus, MD41 for the International Extranodal Study Group (IELSG)* | Extranodal, Primary CNS, DLBCL | IELSG32, MATRIx |
| 2017 | Journal of clinical oncology | Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma, | Luminari S, Ferrari A, Manni M, Dondi A, Chiarenza A, Merli F, Rusconi C, Tarantino V, Tucci A, Vitolo U, Kovalchuk S, Angelucci E, Pulsoni A, Arcaini L, Angrilli F, Gaidano G, Stelitano C, Bertoldero G, Cascavilla N, Salvi F, Ferreri AJM, Vallisa D, Marcheselli L, Federico M | FL | FOLL05 |
| 2017 | BMC Bioinformatics | HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data | Marco Beccuti 1, Elisa Genuardi 2, Greta Romano 1, Luigia Monitillo 2, Daniela Barbero 2, Mario Boccadoro 2, Marco Ladetto 3, Raffaele Calogero 4, Simone Ferrero 2, Francesca Cordero 5 | MRD | |
| 2016 | Physica Medica | The (68)Ge phantom-based FDG-PET site qualification program for clinical trials adopted by FIL (Italian Foundation on Lymphoma), | Chauvie S, Bergesio F, Fioroni F, Brambilla M, Biggi A, Versari A, Guerra L, Storto G, Musto P, Luminari S, Cabras MG, Balzarotti M, Rigacci L, Martelli M, Vitolo U, Federico M, Gallamini A, | PET | |
| 2016 | Haematologica | Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma, A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi | Luminari S1, Galimberti S2, Versari A3, Biasoli I4, Anastasia A5, Rusconi C6, Ferrari A7, Petrini M2, Manni M8, Federico M8, | PET, MRD, FL | FOLL05 |
| 2016 | Leukemia & Lymphoma | A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma | Luminari S1, Goldaniga M2, Cesaretti M1, Orsucci L3, Tucci A4, Pulsoni A5, Salvi F6, Arcaini L7, Carella AM8, Tedeschi A9, Pinto A10, Stelitano C11, Baldini L2, | Indolent non-FL non-Hodgkin Lymphoma | INFL09 |
| 2016 | Leukemia & Lymphoma | B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of theFondazione Italiana Linfomi (FIL) | Balzarotti M1, Brusamolino E1,2, Angelucci E3, Carella AM4, Vitolo U5, Russo E6, Congiu A4, Gotti M2, Massidda S3, Botto B5, Annechini G6, Spina M7, Re A8, Zilioli VR9, Merli F10, Salvi F11, Stelitano C12, Bonfichi M2, Rodari M1, Murru R3, Magagnoli M1, Anastasia A1,8, Mazza R1, Giordano L1,Santoro A1,13, | Hodgkin Lymphoma | B-IGEV, BIGEV |
| 2016 | Journal of clinical oncology | Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study | Zinzani PL1, Broccoli A2, Gioia DM2, Castagnoli A2, Ciccone G2, Evangelista A2, Santoro A2, Ricardi U2, Bonfichi M2, Brusamolino E2, Rossi G2, Anastasia A2, Zaja F2, Vitolo U2, Pavone V2, Pulsoni A2, Rigacci L2, Gaidano G2, Stelitano C2, Salvi F2, Rusconi C2, Tani M2, Freilone R2, Pregno P2, Borsatti E2,Sacchetti GM2, Argnani L2, Levis A2, | PET, Hodgkin Lymphoma | HD0801 |
| 2016 | British journal of haematology | Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL), | Zallio F,, Tamiazzo S,, Monagheddu C,, Merli F,, Ilariucci F,, Stelitano C,, Liberati AM,, Mannina D,,Vitolo U,, Angelucci E,, Rota Scalabrini D,, Vallisa D,, Bellei M,, Bari A,, Ciccone G,, Salvi F,, Levis A, | Hodgkin Lymphoma | VEPEMB vs ABVD |
| 2016 | Thrombosis Research | PO-03 - Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL) | R M Santi 1, M Ceccarelli 2, G Catania 3, C Monagheddu 2, A Evangelista 4, E Bernocco 5, F Monaco 6, M Federico 7, U Vitolo 8, S Cortelazzo 9, M G Cabras 10, M Spina 11, L Baldini 12, C Boccomini 13, A Chiappella 14, A Bari 15, S Luminari 16, M Calabrese 17, A Levis 18, C Visco 19, L Contino 1, G Ciccone 20, M Ladetto 21 | Venous tromboembolism, VTE | |
| 2016 | The Lancet Haematology | Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial | Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rudà R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gørløv JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG), | Extranodal, Primary CNS, DLBCL | IELSG32, MATRIx |
| 2016 | Journal of clinical oncology | Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi | Merli F1, Luminari S2, Gobbi PG2, Cascavilla N2, Mammi C2, Ilariucci F2, Stelitano C2, Musso M2, Baldini L2, Galimberti S2, Angrilli F2, Polimeno G2, Scalzulli PR2, Ferrari A2, Marcheselli L2, Federico M2, | Hodgkin Lymphoma | HD2000 |
| 2016 | Journal of Hematology & Oncology | A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients | Pellegrini C, Dodero A, Chiappella A, Monaco F, Degl'Innocenti D, Salvi F, Vitolo U, Argnani L, Corradini P, Zinzani PL | T-Cell Lymphoma, PTCL | GEMRO |
| 2016 | Haematologica | Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi | Stefano Sacchi 1, Raffaella Marcheselli 2, Alessia Bari 2, Gabriele Buda 3, Anna Lia Molinari 4, Luca Baldini 5, Daniele Vallisa 6, Marina Cesaretti 2, Pellegrino Musto 7, Sonia Ronconi 8, Giorgina Specchia 9, Franco Silvestris 10, Luciano Guardigni 11, Angela Ferrari, Annalisa Chiapella 12, Angelo Michele Carella 13, Armando Santoro 14, Francesco Di Raimondo 15, Luigi Marcheselli 2, Samantha Pozzi 2 | Indolent non-FL non-Hodgkin Lymphoma | INFL08 |
| 2016 | Hematological Oncology | Pitfalls and major issues in the histologic diagnosis of peripheral T-cell lymphomas: results of the central review of 573 cases from the T-Cell Project, an international, cooperative study | Monica Bellei 1, Elena Sabattini 2, Emanuela Anna Pesce 1, Young-Hyeh Ko 3, Won Seog Kim 4, Maria Elena Cabrera 5, Virginia Martinez 6, Ivan Dlouhy 7, Roberto Pinto Paes 8, Tomas Barrese 8, Josè Vassallo 9, Vittoria Tarantino 1, Julie Vose 10, Dennis Weisenburger 11, Thomas Rüdiger 12, Massimo Federico 1, Stefano Pileri 13 14 | T-Cell Lymphoma, PTCL | T-Cell Project |
| 2016 | Physica Medica | The (68)Ge phantom-based FDG-PET site qualification program for clinical trials adopted by FIL (Italian Foundation on Lymphoma) | Stephane Chauvie 1, Fabrizio Bergesio 2, Federica Fioroni 3, Marco Brambilla 4, Alberto Biggi 2, Annibale Versari 3, Luca Guerra 5, Giovanni Storto 6, Pellegrino Musto 6, Stefano Luminari 7, Maria G Cabras 8, Monica Balzarotti 9, Luigi Rigacci 10, Maurizio Martelli 11, Umberto Vitolo 12, Massimo Federico 7, Andrea Gallamini 1 | PET | |
| 2016 | Future oncology | ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma, | Nowakowski GS, Chiappella A, Witzig TE, Spina M, Gascoyne RD, Zhang L, Flament J, Repici J, Vitolo U, | ABC, DLBCL | ROBUST |
| 2016 | Journal of clinical oncology | Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study | Armando Santoro, Rita Mazza, Alessandro Pulsoni, Alessandro Re, Maurizio Bonfichi, Vittorio Ruggero Zilioli, Flavia Salvi, Francesco Merli, Antonella Anastasia, Stefano Luminari, Giorgia Annechini, Manuel Gotti, Annalisa Peli, Anna Marina Liberati, Nicola Di Renzo, Luca Castagna, Laura Giordano, and Carmelo Carlo-Stella | Hodgkin Lymphoma | BeGEV |
| 2016 | Hematological oncology | Training improves the interobserver agreement of the expert positron emission tomography review panel in primary mediastinal B-cell lymphoma: interim analysis in the ongoing International Extranodal Lymphoma Study Group-37 study. | Ceriani L, Barrington S, Biggi A, Malkowski B, Metser U, Versari A, Martelli M, Davies A, Johnson PW, Zucca E, Chauvie S. | PET, PMBCL | IELSG37 |
| 2016 | International Journal of Radiation Oncology Biology Physics | PET/CT assessment after immunochemotherapy and irradiation using the Lugano Classification criteria in the IELSG-26 study of primary mediastinal B-cell lymphoma | L, Ceriani1, M, Martelli2, M,K, Gospodarowicz16, U, Ricardi, A,J,M, Ferreri4, U, Vitolo5, C, Stelitano6, M, Balzarotti, M,E, Cabrera, D,Cunningham, A, Guarini , P,L, Zinzani3, L, Giovanella1, P,W,M, Johnson17, and E, Zucca15, | PET, PMBCL | IELSG26 |
| 2016 | Journal of clinical oncology | Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas | Cortelazzo S, Tarella C, Gianni AM, Ladetto M, Barbui AM, Rossi A, Gritti G, Corradini P, Di Nicola M, Patti C, Mulé A, Zanni M, Zoli V, Billio A, Piccin A, Negri G, Castellino C, Di Raimondo F, Ferreri AJ, Benedetti F, La Nasa G, Gini G, Trentin L, Frezzato M, Flenghi L, Falorio S, Chilosi M, Bruna R, Tabanelli V, Pileri S, Masciulli A, Delaini F, Boschini C, Rambaldi A, | DLBCL | R-CHOP vs HDS (GITIL), RHDS0305 |
| 2015 | Haematologica | The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefitfrom doxorubicin: FIL-FOLL study, | Rossi D1, Bruscaggin A1, La Cava P2, Galimberti S3, Ciabatti E3, Luminari S4, Rigacci L5, Tucci A6, Pulsoni A7, Bertoldero G8, Vallisa D9, Rusconi C10, Spina M11, Arcaini L12, Angrilli F13, Stelitano C14, Merli F15, Gaidano G1, Federico M4, Palumbo GA16 | FL | FILL-FOLL |
| 2015 | American Journal of Hematology | The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi | Giuseppe Rossi 1, Luigi Marcheselli, Alessandra Dondi, Chiara Bottelli, Alessandra Tucci, Stefano Luminari, Luca Arcaini, Michele Merli, Alessandro Pulsoni, Carola Boccomini, Benedetta Puccini, Moira Micheletti, Giovanni Martinelli, Andrea Rossi, Vittorio Ruggero Zilioli, Valentina Bozzoli, Monica Balzarotti, Silvia Bolis, Maria Giuseppina Cabras, Massimo Federico | FL | REFOLL |
| 2015 | Leukemia & Lymphoma | Comparison of different DNA extraction methods from peripheral blood cells: advice from the Fondazione Italiana Linfomi Minimal Residual Disease Network | Claudia Mannu 1, Anna Gazzola 1, Elena Ciabatti 2, Fabio Fuligni 1, Marzia Cavalli 3, Irene Della Starza 3, Elisa Genuardi 4, Barbara Mantoan 4, Luigia Monitillo 4, Ilaria Del Giudice 3, Marco Ladetto 4, Gianluca Gaidano 5, Elena Sabattini 1, Stefano A Pileri 1, Sara Galimberti 2, Pier Paolo Piccaluga 1, Fondazione Italiana Linfomi Minimal Residual Disease Network | MRD, DNA extraction | |
| 2015 | Leukemia & Lymphoma | Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL) | Tucci A1, Martelli M, Rigacci L, Riccomagno P, Cabras MG, Salvi F, Stelitano C, Fabbri A, Storti S, Fogazzi S, Mancuso S, Brugiatelli M, Fama A, Paesano P, Puccini B, Bottelli C, Dalceggio D, Bertagna F, Rossi G, Spina M; Italian Lymphoma Foundation (FIL), | CGA, Elderly | |
| 2015 | British journal of haematology | Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi, | Marcheselli L1, Bari A, Anastasia A, Botto B, Puccini B, Dondi A, Carella AM, Alvarez I, Chiarenza A, Arcari A, Salvi F, Federico M, | FL | FOLL05 |
| 2015 | American Journal of Hematology | The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL) | Rigacci L1, Puccini B1, Zinzani PL2, Biggi A3, Castagnoli A4, Merli F5, Balzarotti M6, Stelitano C7, Spina M8, Vitolo U9, Stefoni V2, Levis A10, Gotti M11, Rosaria S12, Maria SP13, Bosi A1, Gallamini A14, | PET, Hodgkin Lymphoma | |
| 2015 | Oncologist | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41) | Jackson AE, Mian M, Kalpadakis C, Pangalis GA, Stathis A, Porro E, Conconi A, Cortelazzo S, Gaidano G, Lopez Guillermo A, Johnson PW, Martelli M, Martinelli G, Thieblemont C, McPhail ED, Copie-Bergman C, Pileri SA, Jack A, Campo E, Mazzucchelli L, Ristow K, Habermann TM, Cavalli F, Nowakowski GS, Zucca E, | Extranodal, MALT | IELSG41 |
| 2015 | Blood | Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma | Ceriani L1, Martelli M2, Zinzani PL3, Ferreri AJ4, Botto B5, Stelitano C6, Gotti M7, Cabras MG8, Rigacci L9, Gargantini L10, Merli F11, Pinotti G12, Mannina D13, Luminari S14, Stathis A1, Russo E2, Cavalli F1, Giovanella L1, Johnson PW15, Zucca E1, | PET, PMBCL | IELSG26 |
| 2015 | Practical radiation oncology | Interobserver variability in clinical target volume delineation for primary mediastinal B-cell lymphoma, | Piva C1, Genovesi D2, Filippi AR3, Balducci M4, Barra S5, Buglione M6, Busetto M7, Ciammella P8, Franzone P9, De Sanctis V10, Simontacchi G11, Fusella M12, Ricardi U1; Radiation Oncology Committee of the Italian Lymphoma Foundation (FIL), | PET, PMBCL | IELSG26 |
| 2015 | Journal of clinical oncology | High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial | Ferreri AJ1, Donadoni G2, Cabras MG2, Patti C2, Mian M2, Zambello R2, Tarella C2, Di Nicola M2, D'Arco AM2, Doa G2, Bruno-Ventre M2, Assanelli A2, Foppoli M2, Citterio G2, Fanni A2, Mulè A2, Caligaris-Cappio F2, Ciceri F2 | Systemic B-Cell Lymphoma and Secondary CNS Involvement | SCSNL1 |
| 2015 | Leukemia & Lymphoma | Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study | Iannitto E1, Luminari S2, Tripodo C3, Mancuso S1, Cesaretti M2, Marcheselli L2, Merli F4, Stelitano C5, Carella AM6, Fragasso A7, Montechiarello E5, Ricciuti G8, Pulsoni A9, Paulli M10, Franco V3, Federico M2, | SMZL, Splenic Marginal Zone Lymphonma | |
| 2014 | Leukemia & Lymphoma | Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: results from a study of the Fondazione Italiana Linfomi | Merli F1, Luminari S, Rossi G, Mammi C, Marcheselli L, Ferrari A, Spina M, Tucci A, Stelitano C, Capodanno I, Fragasso A, Baldini L, Bottelli C, Montechiarello E, Fogazzi S, Lamorgese C, Cavalli L, Federico M; Fondazione Italiana Linfomi, | Elderly, DLBCL | |
| 2014 | Leukemia & Lymphoma | Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3-5 October 2012 | Michel Meignan 1, Sally Barrington, Emmanuel Itti, Andrea Gallamini, Corinne Haioun, Aaron Polliack | PET | |
| 2014 | Annals of Oncology | The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL) | S Luminari 1, I Biasoli, A Versari, S Rattotti, C Bottelli, C Rusconi, F Merli, M Spina, A J M Ferreri, P L Zinzani, A Gallamini, A Franceschetto, C Boccomini, S Franceschetti, F Salvi, F D Raimondo, A M Carella, Q Micol, M Balzarotti, P Musto, M Federico | PET, FL | FOLL05 |
| 2014 | New England Journal of Medicin | The role of myeloablation for lymphoma | Norbert Schmitz, Marita Ziepert, Umberto Vitolo, German High-Grade Non-Hodgkin’s Lymphoma Study Group; Fondazione Italiana Linfomi | Allo-transplantation | |
| 2014 | Haematologica | Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi | Merli M1, Visco C, Spina M, Luminari S, Ferretti VV, Gotti M, Rattotti S, Fiaccadori V, Rusconi C, Targhetta C, Stelitano C, Levis A, Ambrosetti A, Rossi D, Rigacci L, D'Arco AM, Musto P, Chiappella A, Baldini L, Bonfichi M, Arcaini L, | HCV+, DLBCL | |
| 2014 | Journal of clinical oncology | Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial | Raemaekers JM1, André MP, Federico M, Girinsky T, Oumedaly R, Brusamolino E, Brice P, Fermé C, van der Maazen R, Gotti M, Bouabdallah R, Sebban CJ, Lievens Y, Re A, Stamatoullas A, Morschhauser F, Lugtenburg PJ, Abruzzese E, Olivier P, Casasnovas RO, van Imhoff G, Raveloarivahy T, Bellei M, van der Borght T, Bardet S, Versari A, Hutchings M, Meignan M, Fortpied C, | RT, PET, Hodgkin Lymphoma | EORTC/LySA/FIL 20051 - H10 |
| 2014 | The Lancet Oncology | Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial | Vitolo U1, Chiappella A2, Franceschetti S3, Carella AM4, Baldi I5, Inghirami G6, Spina M7, Pavone V8, Ladetto M9, Liberati AM10, Molinari AL11, Zinzani P12, Salvi F13, Fattori PP14, Zaccaria A15, Dreyling M16, Botto B2, Castellino A2, Congiu A4, Gaudiano M6, Zanni M9, Ciccone G17, Gaidano G3, Rossi G18; Fondazione Italiana Linfomi, | Elderly | REAL07 |
| 2014 | Journal of clinical oncology | [18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study, | Martelli M1, Ceriani L1, Zucca E2, Zinzani PL1, Ferreri AJ1, Vitolo U1, Stelitano C1, Brusamolino E1, Cabras MG1, Rigacci L1, Balzarotti M1, Salvi F1, Montoto S1, Lopez-Guillermo A1, Finolezzi E1, Pileri SA1, Davies A1, Cavalli F1, Giovanella L1, Johnson PW1, | Extranodal, PMBCL | IELSG26 |
| 2014 | Annals of Oncology | Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi | Arcaini L1, Vallisa D2, Rattotti S3, Ferretti VV3, Ferreri AJ4, Bernuzzi P2, Merli M5, Varettoni M3, Chiappella A6, Ambrosetti A7, Tucci A8, Rusconi C9, Visco C10, Spina M11, Cabras G12, Luminari S13, Tucci M14, Musto P15, Ladetto M16, Merli F17, Stelitano C18, d'Arco A19, Rigacci L20, Levis A21, Rossi D22, Spedini P23, Mancuso S24, Marino D25, Bruno R26, Baldini L27, Pulsoni A28, | HCV+, indolent B-cell lymphoma | |
| 2014 | British journal of haematology | Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi | Anastasia, A,, Carlo-Stella, C,, Corradini, P,, Salvi, F,, Rusconi, C,, Pulsoni, A,, Hohaus, S,, Pregno, P,, Viviani, S,, Brusamolino, E,, Luminari, S,, Giordano, L,, and Santoro A, | Hodgkin Lymphoma | |
| 2014 | Leukemia | Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosedpatients with peripheral T-cell lymphoma | Corradini P1, Vitolo U2, Rambaldi A3, Miceli R4, Patriarca F5, Gallamini A6, Olivieri A7, Benedetti F8, Todeschini G8, Rossi G9, Salvi F10, Bruno B2, Baldini L11, Ferreri A12, Patti C13, Tarella C14, Pileri S15, Dodero A16, on behalf of Fondazione Italiana Linfomi | Peripheral T-cell Lymphoma, PTCL | |
| 2014 | The Lancet Haematology | Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies | Judith Trotman 1, Stefano Luminari 2, Sami Boussetta 3, Annibale Versari 4, Jehan Dupuis 5, Christelle Tychyj 6, Luigi Marcheselli 2, Alina Berriolo-Riedinger 7, Antonella Franceschetto 2, Anne Julian 8, Fabien Ricard 9, Luca Guerra 10, Corinne Haioun 11, Irene Biasoli 12, Hervé Tilly 13, Massimo Federico 2, Gilles Salles 14, Michel Meignan 15 | PET, FL | |
| 2014 | Clinical cancer research | Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial | Galimberti S1, Luminari S2, Ciabatti E3, Grassi S4, Guerrini F4, Dondi A2, Marcheselli L2, Ladetto M5, Piccaluga PP6, Gazzola A6, Mannu C6, Monitillo L5, Mantoan B5, Del Giudice I7, Della Starza I7, Cavalli M7, Arcaini L8, Tucci A9, Palumbo GA10, Rigacci L11, Pulsoni A7, Vitolo U5, Boccomini C5, Vallisa D12, Bertoldero G13, Gaidano G14, Musto P15, Petrini M4, Federico M2, | MRD, FL | FOLL05 |
| 2013 | Leukemia & Lymphoma | Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study, | Carella AM, de Souza CA, Luminari S, Marcheselli L, Chiappella A, di Rocco A, Cesaretti M, Rossi A, Rigacci L, Gaidano G, Merli F, Spina M, Stelitano C, Hohaus S, Barbui A, Puccini B, Miranda EC, Guida A, Federico M, | DLBCL | |
| 2013 | Journal of clinical oncology | R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi | Federico M1, Luminari S, Dondi A, Tucci A, Vitolo U, Rigacci L, Di Raimondo F, Carella AM, Pulsoni A, Merli F, Arcaini L, Angrilli F, Stelitano C, Gaidano G, Dell'olio M, Marcheselli L, Franco V, Galimberti S, Sacchi S, Brugiatelli M, | FL | FOLL05 |
| 2013 | Journal of clinical oncology | Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi | Vitolo U1, Ladetto M, Boccomini C, Baldini L, De Angelis F, Tucci A, Botto B, Chiappella A, Chiarenza A, Pinto A, De Renzo A, Zaja F, Castellino C, Bari A, Alvarez De Celis I, Evangelista A, Parvis G, Gamba E, Lobetti-Bodoni C, Ciccone G, Rossi G, | Elderly, FL | R-FND |
| 2013 | Leukemia & Lymphoma | Role of radiotherapy in patients with early-stage diffuse large B-cell lymphoma of Waldeyer's ring in remission after anthracycline-containing chemotherapy | Mian M1, Ferreri AJ, Rossi A, Conconi A, Tsang R, Gospodarowicz MK, Oldani E, Federico M, Luminari S, Pogliani EM, Rossini F, Cabrera ME, Martelli M, Gutierrez-Garcia G, Busetto M, Cavalli F, Zucca E, Rambaldi A, Cortelazzo S; International Extranodal Lymphoma Study Group (Ielsg), | RT, DLBCL | |
| 2013 | Annals of Oncology | The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi | Luminari S1, Biasoli I, Arcaini L, Versari A, Rusconi C, Merli F, Spina M, Ferreri AJ, Zinzani PL, Gallamini A, Mastronardi S, Boccomini C, Gaidano G, D'Arco AM, Di Raimondo F, Carella AM, Santoro A, Musto P, Federico M, | PET, FL | FOLL05 |
| 2013 | Annals of Hematology | Early-stage diffuse large B-cell lymphoma of the head and neck:clinico-biological characterization and 18 years follow-up of 488 patients (IELSG 23 study) | M,Mian, D,Capello, M,Bruno Ventre, D,Grazio, M,Svaldi, A,Rossi, D,Rossi, G,Gaidano, R, Tsang, M,K, Gospodarowicz, E,Oldani, M,Federico, S,Luminari, E,M,Pogliani, F,Rossini, M, E, Cabrera, M, Martelli, G,Gutierrez - Garcia, M,Busetto, C,Visco, M,Fiegl, F,Cavalli, E,Zucca, A,Rambaldi, S,Cortelazzo on behalf of the International Extranodal Lymphoma Study Group (IELSG), | Extranodal, Head and Neck, DLBCL | IELSG23 |
| 2013 | Haematologica | Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi | Chiappella A1, Tucci A, Castellino A, Pavone V, Baldi I, Carella AM, Orsucci L, Zanni M, Salvi F, Liberati AM, Gaidano G, Bottelli C, Rossini B, Perticone S, De Masi P, Ladetto M, Ciccone G, Palumbo A, Rossi G, Vitolo U; Fondazione Italiana Linfomi, | Elderly, DLBCL | |
| 2013 | Blood | Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program | Marco Ladetto 1, Chiara Lobetti-Bodoni, Barbara Mantoan, Manuela Ceccarelli, Carola Boccomini, Elisa Genuardi, Annalisa Chiappella, Luca Baldini, Giuseppe Rossi, Alessandro Pulsoni, Francesco Di Raimondo, Luigi Rigacci, Antonello Pinto, Sara Galimberti, Alessia Bari, Delia Rota-Scalabrini, Angela Ferrari, Francesco Zaja, Andrea Gallamini, Giorgina Specchia, Pellegrino Musto, Francesca Gaia Rossi, Enrica Gamba, Andrea Evangelista, Umberto Vitolo, Fondazione Italiana Linfomi | MRD, FL | |
| 2012 | Leukemia & Lymphoma | Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi | Merli F, Luminari S, Rossi G, Mammi C, Marcheselli L, Tucci A, Ilariucci F, Chiappella A, Musso M, Di Rocco A, Stelitano C, Alvarez I, Baldini L, Mazza P, Salvi F, Arcari A, Fragasso A, Gobbi PG, Liberati AM, Federico M, | Elderly, DLBCL | ANZINTER3 |
| 2012 | Annals of Hematology | Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients: A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL) | Rigacci L, Puccini B, Cortelazzo S, Gaidano G, Piccin A, D'Arco A, Freilone R, Storti S, Orciuolo E, Zinzani PL, Zaja F, Bongarzoni V, Balzarotti M, Rota-Scalabrini D, Patti C, Gobbi M, Carpaneto A, Liberati AM, Bosi A, Iannitto E, | Non-Hodgkin Lymphoma | |
| 2012 | Blood | Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination | Benevolo G, Stacchini A, Spina M, Ferreri AJ, Arras M, Bellio L, Botto B, Bulian P, Cantonetti M, Depaoli L, Di Renzo N, Di Rocco A, Evangelista A, Franceschetti S, Godio L, Mannelli F, Pavone V, Pioltelli P, Vitolo U, Pogliani EM; on behalf of the Fondazione Italiana Linfomi | Non-Hodgkin Lymphoma | |
| 2012 | Haematologica | Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers | Zaja F, De Luca S, Vitolo U, Orsucci L, Levis A, Salvi F, Rusconi C, Ravelli E, Tucci A, Bottelli C, Balzarotti M, Brusamolino E, Bonfichi M, Pileri SA, Sabattini E, Volpetti S, Monagheddu C, Vacca A, Ria R, Fanin R, | MCL | |
| 2012 | Journal of Clinical Oncology | Watchful Waiting in Low–Tumor Burden Follicular Lymphoma in the Rituximab Era: Results of an F2-Study Database | Solal-Celigny P, Bellei M, Marcheselli L, Pesce EA, Pileri S, McLaughlin P, Luminari S, Pro B, Montoto S, Ferreri AJ, Deconinck E, Milpied N, Gordon LI, Federico M, J, Clin, Oncol, 2012 | FL | F2-STUDY |
| 2011 | Leukemia & Lymphoma | High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano study | Mian M, Gaidano G, Conconi A, Tsang R, Gospodarowicz MK, Rambaldi A, Rossi A, Oldani E, Federico M, Luminari S, Bellei M, Pogliani EM, Rossini F, Cabrera ME, Martelli M, Lopez-Guillermo A, Busetto M, Cavalli F, ZuccaE, Cortellazzo S, | Extranodal, Primary Tyroid, DLBCL | IELSG |
| 2011 | Annals of Hematology | CLIPI: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11) | Mian M, Marcheselli L, Luminari S, Federico M, Cantonetti M, Sarris AH, Rossi A, Rambaldi A, Frontani M, Devizzi L, Gianni AM, Busetto M, Berti E, Martinelli G, Tsang RW, Ferreri AJ, Pinotti G, Pogliani E, Zucca E, Cortelazzo S, | Extranodal, Cutaneous B-cell, indolent | IELSG11 |
| 2011 | Oncologist | Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combination | Ferreri AJ, Licata G, Foppoli M, Corazzelli G, Zucca E, Stelitano C, Zaja F, Fava S, Paolini R, Franzin A, Politi LS, Ponzoni M, Reni M, | Extranodal, Primary CNS, DLBCL | IELSG |
| 2011 | Annals of Oncology | Clinical activity of bortezomib in relapsed/refractory malt lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG) | Conconi A, Martinelli G, Lopez-Guillermo A, Zinzani PL, Ferreri AJ, Rigacci L, Devizzi L, Vitolo U, Luminari S, Cavalli F, Zucca E, | Extranodal, MALT | IELSG |
| 2011 | Journal of clinical oncology | First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial | Vitolo U, Chiappella A, Ferreri AJ, Martelli M, Baldi I, Balzarotti M, Bottelli C, Conconi A, Gomez H, Lopez-Guillermo A, Martinelli G, Merli F, Novero D, Orsucci L, Pavone V, Ricardi U, Storti S, Gospodarowicz MK, Cavalli F, Sarris AH, Zucca E, | Extranodal, Primary testicular, DLBCL | IELSG10 |
| 2011 | New England Journal of Medicin | ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned | Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, Vitolo U, Pulsoni A, Liberati AM, Specchia G, Valagussa P, Rossi A, Zaja F, Pogliani EM, Pregno P, Gotti M, Gallamini A, Rota Scalabrini D, Bonadonna G, Gianni AM; Michelangelo Foundation; | Hodgkin Lymphoma | ABVD vs BEACOPP IIL |
| 2011 | Journal of clinical oncology | Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi | Chisesi T, Bellei M, Luminari S, Montanini A, Marcheselli L, Levis A, Gobbi P, Vitolo U, Stelitano C, Pavone V, Merli F, Liberati M, Baldini L, Bordonaro R, Pesce EA, Federico M, | Hodgkin Lymphoma | MOPP/EBV/CAD (HD9601) |